Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT01502488	Adipose Derived Stem Cell Therapy for Autism		Withdrawn	No Results Available	Autism	Procedure: Fat Harvesting and Stem Cell Injection	Improvement in the Childhood Autism Rating Scale，CARS|Improvement in the Clinical Global Impression Scale, CGI|Improvement in the Aberrant Behavior Checklist, ABC	Ageless Regenerative Institute|Instituto de Medicina Regenerativa	All	3 Years to 12 Years   (Child)	Phase 1|Phase 2	0	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ADI-AT-001	October 2016	November 2017	January 2018	December 30, 2011		July 21, 2017	Ageless Regenerative Institute LLC, Aventura, Florida, United States		https://ClinicalTrials.gov/show/NCT01502488
2	NCT01999894	Open-label Study of Safety and Tolerability of Memantine in Children With Autism		Completed	Has Results	Autism|Pediatric Autism	Drug: Memantine HCl	Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)	Forest Laboratories|Merz Pharmaceuticals GmbH	All	6 Years to 18 Years   (Child, Adult)	Phase 2	102	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MEM-MD-67	November 2009	February 2013	February 2013	December 3, 2013	March 18, 2014	March 18, 2014	Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 003, Sacramento, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 020, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 024, Jacksonville Beach, Florida, United States|Forest Investigative Site 007, St. Petersburg, Florida, United States|Forest Investigative Site 014, Hoffman Estates, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 010, Indianapolis, Indiana, United States|Forest Investigative Site 025, Cambridge, Massachusetts, United States|Forest Investigative Site 011, Toms River, New Jersey, United States|Forest Investigative Site 006, Voorhees, New Jersey, United States|Forest Investigative Site 017, Manhasset, New York, United States|Forest Investigative Site 013, Cleveland, Ohio, United States|Forest Investigative Site 015, Cleveland, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma, Oklahoma, United States		https://ClinicalTrials.gov/show/NCT01999894
3	NCT00872898	Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism		Completed	Has Results	Autism	Drug: Memantine - Extended Release (ER)|Drug: Placebo	Extent of Absorption of Memantine (Part One)|Change in Total Raw Score of Social Responsiveness Scale|Core Autism Treatment Scale-Improvement: Total Score|Core Autism Treatment Scale-Improvement: Social Interaction|Core Autism Treatment Scale-Improvement: Communication|Change in Children's Communication Checklist-2 (CCC-2) - Speech Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Context Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Interests Subscale	Forest Laboratories|Merz Pharmaceuticals GmbH	All	6 Years to 18 Years   (Child, Adult)	Phase 2	124	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MEM-MD-57A	April 2009	August 2012		March 31, 2009	January 14, 2014	January 14, 2014	Forest Investigative Site, Phoenix, Arizona, United States|Forest Investigative Site, Sacramento, California, United States|Forest Investigative Site, San Francisco, California, United States|Forest Investigative Site, Santa Ana, California, United States|Forest Investigative Site, Stanford, California, United States|Forest Investigative Site, Jacksonville Beach, Florida, United States|Forest Investigative Site, St Petersburg, Florida, United States|Forest Investigative Site, Hoffman Estates, Illinois, United States|Forest Investigative site, Naperville, Illinois, United States|Forest Investigative Site, Indianapolis, Indiana, United States|Forest Investigative Site, Cambridge, Massachusetts, United States|Forest Investigative Site, Toms River, New Jersey, United States|Forest Investigative Site, Voorhees, New Jersey, United States|Forest Investigative Site, Manhasset, New York, United States|Forest Investigative Site, Cleveland, Ohio, United States|Forest Investigative Site, Columbus, Ohio, United States|Forest Investigative Site, Oklahoma City, Oklahoma, United States		https://ClinicalTrials.gov/show/NCT00872898
4	NCT04258839	Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148		Unknown status	No Results Available	Irritability Associated With Autism Spectrum Disorder	Drug: Brexpiprazole	Adverse Events|Aberrant Behavior Checklist (ABC-I)|Clinical Global Impression (CGI-S)	Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S	All	5 Years to 17 Years   (Child)	Phase 3	100	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	331-201-00191	January 17, 2020	August 20, 2022	August 20, 2022	February 6, 2020		May 28, 2020	For additional information regarding sites, Princeton, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04258839
5	NCT04174365	Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder	Anchor	Unknown status	No Results Available	Irritability Associated With Autism Spectrum Disorder (ASD)	Drug: Brexpiprazole|Drug: Placebo	The mean change from baseline to Week 8 in the Aberrant Behavior Checklist- Irritability subscale score (ABC-I)|The mean change from baseline to Week 8 in the Clinical Global Impression- Severity of Illness Scale (CGI-S) score pertaining to irritability	Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S	All	5 Years to 17 Years   (Child)	Phase 3	130	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	331-201-00148	October 30, 2019	February 23, 2022	February 23, 2022	November 22, 2019		May 28, 2020	For additional information regarding sites, Princeton, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04174365
6	NCT02649959	An Open Label Study of CM-AT for the Treatment of Children With Autism		Active, not recruiting	No Results Available	Autism	Drug: CM-AT	Aberrant Behavioral Checklist: Subscale of Irritability / Agitation (ABC-I) at fecal chymotrypsin (FCT) levels less than or equal to 12.6|Aberrant Behavior Checklist: Subscale of Lethargy / Social Withdrawal (ABC-L) at fecal chymotrypsin (FCT) levels less than or equal to 12.6	Curemark	All	3 Years to 17 Years   (Child)	Phase 3	405	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	00104/Open Label-Autism	October 2015	January 2023	June 2023	January 8, 2016		August 3, 2022	Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix, Arizona, United States|University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson, Arizona, United States|Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock, Arkansas, United States|N.R.C. Research Institute, Orange, California, United States|M.I.N.D. Institute (Univ.of California, Davis), Sacramento, California, United States|University of California (U.C.S.F.), San Francisco, California, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|Yale Child Study Center, New Haven, Connecticut, United States|Segal Institute For Clinical Research, North Miami, Florida, United States|Advent Health -Lake Mary Pediatrics, Orange City, Florida, United States|A.P.G. Research, Orlando, Florida, United States|Research Institute of Deaconess Clinic, Newburgh, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|L.S.U. Health Sciences Center, Shreveport, Louisiana, United States|Detroit Clinical Research Center, P.C., Bingham Farms, Michigan, United States|Children'S Specialized Hospital, Egg Harbor Township, New Jersey, United States|Barbara Enright, Toms River, New Jersey, United States|Clinical Research Center of Nj, Voorhees, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Montefiore Med.Cneter, Autism & Obsessive Compulsive Spectrum Program, Bronx, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke Center For Autism and Brain Development, Durham, North Carolina, United States|Cleveland Clinic Autism Center, Cleveland, Ohio, United States|Omega Medical Research, Warwick, Rhode Island, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Vanderbilt Universtiy Med.Center-Treatment&Research Inst. For Asd, Nashville, Tennessee, United States|University of Texas, Houston-Behavioral & Biomedical Sciences, Houston, Texas, United States|Focus Center of Clinical Research, Clinton, Utah, United States|University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States|Neuroscience, Inc, Herndon, Virginia, United States|Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke, Virginia, United States		https://ClinicalTrials.gov/show/NCT02649959
7	NCT02410902	A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)		Completed	Has Results	Autism	Drug: CM-AT|Drug: PLACEBO	Primary Outcome Measurements to Determine Efficacy of Treatment With CM-AT Versus Placebo for Changes in the Aberrant Behavior Checklist Subscale for Irritability / Agitation (ABC-I) Between Baseline and Week 12/Termination Visit|Secondary Outcome Measurements of Changes in the Aberrant Behavior Checklist Checklist Subscale for Lethargy / Social Withdrawal (ABC-L) Between Baseline and Week 12/Termination Visit	Curemark	All	3 Years to 8 Years   (Child)	Phase 3	190	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	00103	May 13, 2015	December 22, 2017	December 22, 2017	April 8, 2015	October 26, 2022	October 26, 2022	Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix, Arizona, United States|University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson, Arizona, United States|Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock, Arkansas, United States|N.R.C. Research Institute, Orange, California, United States|M.I.N.D. Institute (Univ.of California, Davis), Sacramento, California, United States|University of California (U.C.S.F.), San Francisco, California, United States|IMMUNOe RESEARCH CENTERS, Centennial, Colorado, United States|Yale Child Study Center, New Haven, Connecticut, United States|Segal Institute For Clinical Research, North Miami, Florida, United States|Florida Hospital Medical Group-Lake Mary Pediatrics, Orange City, Florida, United States|Kaley Kildahl, Orlando, Florida, United States|Research Institute of Deaconess Clinic, Evansville, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|L.S.U. Health Sciences Center, Shreveport, Louisiana, United States|Detroit Clinical Research Center, P.C., Bingham Farms, Michigan, United States|Children'S Specialized Hospital, Egg Harbor Township, New Jersey, United States|Children'S Specialized Hospital, Toms River, New Jersey, United States|Clinical Research Center of Nj, Voorhees, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Montefiore Med.Center, Autism & Obsessive Compulsive Spectrum Prog., Bronx, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke Center For Autism and Brain Development, Durham, North Carolina, United States|Cleveland Clinic, Center For Autism Research, Cleveland, Ohio, United States|Omega Medical Research, Warwick, Rhode Island, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Vanderbilt University Med.Center -Treatment & Research Inst. For Asd, Nashville, Tennessee, United States|University of Texas, Houston Dept. of Psychiatry and Behavioral Sciences, Houston, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke, Virginia, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02410902/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02410902/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02410902
8	NCT00881452	A Trial of CM-AT in Children With Autism	CM-AT	Completed	No Results Available	Autism	Drug: CM-AT|Drug: Placebo	Evidence of changes in behavior scales associated with the core symptoms of autism|Other key measures of behavior and quality of life associated with autism	Curemark	All	3 Years to 8 Years   (Child)	Phase 3	182	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	00101	May 2009	June 2011	September 2011	April 15, 2009		April 19, 2018	Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California, Davis, M.I.N.D. Institute, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Louisiana State University Health Science Center, Shreveport, Louisiana, United States|Saint Peters University Hospital, New Brunswick, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma University Child Study Center, Oklahoma City, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Houston, Houston, Texas, United States|Westside Medical, Clinton, Utah, United States		https://ClinicalTrials.gov/show/NCT00881452
9	NCT00912691	A Trial of CM-AT in Children With Autism- Open Label Extension Study	CM-AT	Completed	No Results Available	Autism	Drug: CM-AT	Evidence of changes in behavior scales associated with the core symptoms of autism|Other key measures of behavior and quality of life associated with autism	Curemark	All	9 Years to 12 Years   (Child)	Phase 3	165	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	00102/Autism	January 2010	February 2016	February 2016	June 3, 2009		March 1, 2019	Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California, Davis, M.I.N.D. Institute, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Louisiana State University, Shreveport, Louisiana, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Mount Sinai School of Medicine, Manhattan, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma State University, Child Study Center, Oklahoma City, Oklahoma, United States|Cyn3rgy Research Center, Gresham, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Universtiy of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Houston, Houston, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States		https://ClinicalTrials.gov/show/NCT00912691
10	NCT01911442	Lurasidone Pediatric Autism Study		Completed	Has Results	Autism	Drug: Lurasidone 20 mg daily|Drug: Lurasidone|Drug: Placebo	Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6|Change From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6|Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score at Week 6|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) Modified for Pervasive Developmental Disorders (PDDs)|Change From Baseline in the Caregiver Strain Questionnaire (CGSQ)|Proportion of Subjects Who Have CGI-I Score of 1 (Very Much Improved) or 2 (Much Improved) at Week 6|Proportion of Subjects Who Have at Least 25% Reduction From Baseline to Week 6 in the ABC Irritability Subscale Score.	Sunovion	All	6 Years to 17 Years   (Child)	Phase 3	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	D1050325	August 2013	November 2014	November 2014	July 30, 2013	February 25, 2016	February 25, 2016	Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Newport Beach Clinical Research Associates, Newport Beach, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|Sarkis Clinical Trials - Parent, Gainesville, Florida, United States|Palm Springs Research Institute Inc, Hialeah, Florida, United States|Florida Clinical Research Center, LLC, Maitland, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|Medical Research Group of Central Florida, Sanford, Florida, United States|University of South Florida, Tampa, Florida, United States|Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States|Capstone Clinical Research, Inc., Libertyville, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|NeuroScientific Insights, Rockville, Maryland, United States|Neurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Childrens Specialized Hospital, Toms River, New Jersey, United States|Montefiore Medical Center PRIME, Bronx, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Chapel Hill Neurology, Chapel Hill, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Cyn3rgy Research & Development, Gresham, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Segal Institute for Clinical Research, Charleston, South Carolina, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Family Psychiatry of The Woodlands, P.A., The Woodlands, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|CRI Lifetree, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Carilion Clinic, Roanake, Virginia, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States		https://ClinicalTrials.gov/show/NCT01911442
11	NCT01388179	Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children.		Terminated	No Results Available	Autism	Device: Transcranial Magnetic Stimulation	CGI-I(clinical global impression-I) as a measure for social functioning|ASRS (Adult ADHD Self Report Scale) as a measure for social awareness and social motivation|Facial recognition test as a measure for preference to faces vs. objects|PLS-4(Preschool Language Scale - 4 ) as a measure for language impairment.|BASC (Behavior Assessment System for Children) as a measure for anxiety|ABC (Autism Behavior Checklist)as a measure for repetitive behaviors	Brainsway|Hadassah Medical Organization	All	10 Years to 18 Years   (Child, Adult)	Phase 2	20	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	TMS-AUTISM	January 23, 2013	December 31, 2016	December 31, 2016	July 6, 2011		April 17, 2018	Hadassah Medical Organization, Jerusalem, Israel		https://ClinicalTrials.gov/show/NCT01388179
12	NCT00332241	Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)		Completed	Has Results	Autistic Disorder	Drug: Aripiprazole|Drug: Placebo	Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score|Mean Clinical Global Impressions Improvement Scale (CGI-I) Score|Number of Participants With Response at Week 8|Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)|Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores|Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)|Summary of Safety|Change From Baseline in Body Weight	Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical	All	6 Years to 17 Years   (Child)	Phase 3	98	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CN138-178	June 2006	April 2008	April 2008	June 1, 2006	July 23, 2009	December 2, 2013	Marsella, Gregory, Boca Raton, Florida, United States|Child Neurology Associates, Pc, Atlanta, Georgia, United States|University Of Louisville, Louisville, Kentucky, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Center For Psychiatry And Behavioral Medicine, Las Vegas, Nevada, United States|Suny - Stony Brook School Of Medicine, Stony Brook, New York, United States|Univ Of Nc, Chapel Hill, North Carolina, United States|Ut Medical Group, Memphis, Tennessee, United States|Red Oak Psychiatry Associates, Pa, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00332241
13	NCT01343511	Safety and Efficacy of Stem Cell Therapy in Patients With Autism		Completed	No Results Available	Autism	Biological: human cord blood mononuclear cells|Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells	Childhood Autism Rating Scale，CARS|Clinical Global Impression Scale，CGI|Aberrant Behavior Checklist，ABC|Adverse Event and Serious Adverse Event	Shenzhen Beike Bio-Technology Co., Ltd.|Shandong Jiaotong Hospital|Association for the Handicapped Of Jinan	All	3 Years to 12 Years   (Child)	Phase 1|Phase 2	37	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BKCR-AUTISM-1.0(2009)	March 2009	June 2010	May 2011	April 28, 2011		October 14, 2011	Shandong Jiaotong Hospital, Jinan, Shandong, China		https://ClinicalTrials.gov/show/NCT01343511
14	NCT02192749	Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism		Completed	No Results Available	Autism	Biological: Umbilical cord mesenchymal stem cells	Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC)	Translational Biosciences	All	6 Years to 16 Years   (Child)	Phase 1|Phase 2	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TBS-UCMSC-ASD001	July 2014	August 2017	August 2017	July 17, 2014		October 13, 2017	Stem Cell Institute, Panama City, Panama		https://ClinicalTrials.gov/show/NCT02192749
15	NCT02947048	Safety of L1-79 in Autism		Completed	No Results Available	Autism	Drug: L1-79|Drug: Placebo	Adverse event frequency|Change from baseline in CGI|Change from Baseline in Vineland Adaptive Behavior Scales - 2nd Edition|Change from Baseline in the Autism Diagnostic Observation Schedule (ADOS)|Change from baseline in Aberrant Behavior Checklist - Community|Change from baseline in the Social Responsiveness Scale - 2nd edition (SRS-2)|Changes from baseline in the Repetitive Behavior Scale - Revised (RBS-R).|Plasma concentrations of L1-79	Yamo Pharmaceuticals LLC	Male	13 Years to 21 Years   (Child, Adult)	Phase 2	42	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HT 02-121	October 2016	December 2017	February 1, 2018	October 27, 2016		January 27, 2022	Eric Bartky MD, Bartky Health Care Center, Livingston, New Jersey, United States|F. Peter Halas MD, Sea Girt Pediatrics, Sea Girt, New Jersey, United States		https://ClinicalTrials.gov/show/NCT02947048
16	NCT02140112	Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder		Terminated	No Results Available	Autism	Biological: Trichuris suis ova|Other: Placebo	Change from Baseline in Aberrant Behavior Checklist - Irritability (ABC-I) at 16 weeks	Coronado Biosciences, Inc.	All	5 Years to 17 Years   (Child)	Phase 2	23	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CNDO 201-101	May 2014	April 2015	April 2015	May 16, 2014		November 4, 2015	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Baber Research Group, Naperville, Illinois, United States|Montefiore Medical Center Dept. of Psychiatry, Child Annex, Bronx, New York, United States|Red Oak Psychiatry, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02140112
17	NCT02720900	Prebiotic Intervention for Autism Spectrum Disorders		Completed	No Results Available	Autism	Dietary Supplement: B-GOS|Dietary Supplement: Maltodextrin	effect on faecal microbiota composition using pyrosequencing|effect on faecal microbiota activity using nuclear magnetic resonance spectroscopy|questionnaire as a measure of bowel function|questionnaire as a measure of mood|questionnaire as a measure of behaviour	Clasado Limited|University of Reading	All	5 Years to 10 Years   (Child)	Not Applicable	41	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ASD2015	September 2015	September 2016	May 2017	March 28, 2016		February 15, 2018	University of Reading, Reading, Berks, United Kingdom		https://ClinicalTrials.gov/show/NCT02720900
18	NCT01064973	An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders		Terminated	No Results Available	Autism Spectrum Disorders	Drug: arbaclofen	Irritability subscale of the Aberrant Behavior Checklist	Seaside Therapeutics, Inc.	All	6 Years to 17 Years   (Child)	Phase 2	32	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	22007	February 2010	December 2012	December 2012	February 9, 2010		December 20, 2012	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01064973
19	NCT04660552	Transcranial Photobiomodulation for Reducing Autism Symptoms in Children	TPBMASD	Recruiting	No Results Available	Autism Spectrum Disorder	Device: Cognilum TM: Light Treatment Condition	Change in Autism symptoms|EEG - 1|EEG - 2	JelikaLite LLC	All	2 Years to 6 Years   (Child)	Not Applicable	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	19751975	November 15, 2020	December 31, 2022	December 30, 2023	December 9, 2020		December 9, 2020	Dr. Steingold Psychology PC, Brooklyn, New York, United States|Dr. Steingold Psychology PC, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04660552
20	NCT04562688	Care Improving Cognition for ADolescents on the Autism Spectrum	CICADAS	Recruiting	No Results Available	Autism Spectrum Disorder	Other: CICADAS and then PEERS|Other: PEERS + CICADAS and then no-contact|Other: PEERS + Active Comparator and then no-contact	Digital Assessment Completion Rate|NB-SCT Program Adherence|Post-Study Usability Ratings|Reported Number of Adverse Effects|Total number of participants who complete the intervention	Posit Science Corporation|University of Minnesota	All	11 Years to 18 Years   (Child, Adult)	Not Applicable	48	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PSC-0909-20	June 11, 2021	December 1, 2022	December 1, 2022	September 24, 2020		September 13, 2022	University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04562688
21	NCT04644003	Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder		Completed	No Results Available	Autism Spectrum Disorder	Drug: STP1|Drug: Placebo	Safety and Tolerability|Plasma concentration of STP1 (PK)	Stalicla SA	All	18 Years to 40 Years   (Adult)	Phase 1	12	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STP1-C004	December 7, 2020	January 28, 2022	January 28, 2022	November 25, 2020		February 17, 2022	Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT04644003
22	NCT05081245	ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)		Recruiting	No Results Available	Autism Spectrum Disorder	Drug: ML-004 (IR)/(ER) tablet|Drug: ML-004 Placebo	Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain Score|Change from Baseline in Clinician Global Impression of Improvement (CGI-I)|Change from Baseline in Autism Behavior Inventory-Clinician (ABI-C) Score|Change from Baseline in Aberrant Behavior Checklist 2-Irritability (ABC-I) Subscale Score|Change from baseline in the Clinician Global Impression of Severity (CGI-S) Score|Change from baseline in the ABI Repetitive/Restrictive Behavior Domain Score|Change from baseline in the ABI Mood and Anxiety Domain Score|Change from baseline in the ABI Challenging Behavior Domain Score|Change from baseline in the ABI Self-regulation Domain Score|Change from baseline in the ABI-Short Form (ABI-S) Score|Change from baseline in the ABC-Social Withdrawal (ABC-SW) Subscale Score|Change from baseline in the Social Responsiveness Scale 2 (SRS-2) Score|Change from baseline in the Vineland-3 (Domain Level Version) Score: total of Communication, Socialization, and Maladaptive behavior domains	MapLight Therapeutics	All	12 Years to 45 Years   (Child, Adult)	Phase 2	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	ML-004-002	August 11, 2022	August 10, 2023	December 31, 2023	October 18, 2021		November 17, 2022	Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Clinical Research, Phoenix, Arizona, United States|APG Research, LLC, Orlando, Florida, United States|University of South Florida Psychiatry and Behavioral Neurosciences, Tampa, Florida, United States|AMR-Baber Research Inc, Naperville, Illinois, United States|University of Missouri, Thompson Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Suburban Research Associates, Media, Pennsylvania, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research, Ltd., San Antonio, Texas, United States|Cedar Clinical Research, Draper, Utah, United States|Brain and Mind Centre, Camperdown, New South Wales, Australia|OCT Research ULC (dba Okanagan Clinical Trials), Kelowna, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT05081245
23	NCT00036244	Synthetic Human Secretin in Children With Autism		Completed	No Results Available	Autism	Drug: RG1068 (Synthetic Human Secretin)		Repligen Corporation	All	32 Months to 59 Months   (Child)	Phase 3		Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	RG1068-04	April 2002		January 2004	May 9, 2002		August 5, 2005	Southwest Autism Research Center, Phoenix, Arizona, United States|UCLA Pediatric Neurology, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|1st Allergy & Clinical Research Center, Centennial, Colorado, United States|Alachua Family Psychiatry, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Riley Children's Hospital, Indianapolis, Indiana, United States|The Clinical Trials Center:A Division of Children's Hospital, Metairie, Louisiana, United States|Hardy Healthcare Associates, Hingham, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|The Ohio State University, Columbus, Ohio, United States|Children's Biomedical Center of Utah, Sandy, Utah, United States|Puget Sound Neurology, Edmonds, Washington, United States		https://ClinicalTrials.gov/show/NCT00036244
24	NCT00036231	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction		Terminated	No Results Available	Autism	Drug: RG1068 (Synthetic Human Secretin)		Repligen Corporation	All	32 Months to 59 Months   (Child)	Phase 3		Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	RG1068-03	April 2002			May 9, 2002		November 21, 2005			https://ClinicalTrials.gov/show/NCT00036231
25	NCT01288716	Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders		Completed	No Results Available	Autism Spectrum Disorders	Drug: Arbaclofen	Aberrant Behavior Checklist-Social Withdrawal Subscale	Seaside Therapeutics, Inc.	All	5 Years to 21 Years   (Child, Adult)	Phase 2	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	209AS208	May 2011	August 2012	September 2012	February 2, 2011		July 31, 2013	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States|Pharmax Research Clinic, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Institute for Juvenile Research, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelpmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Group, LeBonheur Children's Hospital, Memphis, Tennessee, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01288716
26	NCT05067582	A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder		Recruiting	No Results Available	Autism Spectrum Disorder|Autism	Drug: L1-79	Vineland Adaptive Behavior Scale, Third Edition (Vineland-3), Average of the Growth Scale Value (GSV) score of the three Socialization Subdomains (combined)|Brief Observation of Social Communication Change (BOSCC)|Clinical Global Impression of Severity of Illness (CGI-S) weighted for socialization|Clinical Global Impression of Change (CGI-C) weighted for socialization|Percent of subjects showing a statistically significant improvement in GSV on 2 of the Socialization Subdomains|Caregiver Global Impression of Change of 3 Most Bothersome Symptoms of ASD (CGI-3P)|Social Responsiveness Scale, Second Edition (SRS-2) Social-Communication and Interaction - DSM-5 Composite T-score|Social Responsiveness Scale, Second Edition (SRS-2) Total T-score|Social Responsiveness Scale, Second Edition (SRS-2) Social Motivation T-score|Vineland-3 Socialization Domain, Standard Score|Parent-rated Anxiety Scale for ASD (PRAS-ASD)|Child's Sleep Habits Questionnaire (CSHQ)	Yamo Pharmaceuticals LLC	All	12 Years to 21 Years   (Child, Adult)	Phase 2	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Y202	January 25, 2022	February 2023	March 2023	October 5, 2021		March 9, 2022	Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|Thompson Autism Center CHOC, Orange, California, United States|Rush University, Chicago, Illinois, United States|Thompson Center for Autism and Neurodevelopmental Disorders, Columbia, Missouri, United States|Red Oak Psychiatry Associates, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT05067582
27	NCT05439616	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD		Recruiting	No Results Available	Autism Spectrum Disorder	Drug: Cariprazine|Drug: Placebo	Change from Baseline in Aberrant Behavior Checklist, 2nd edition - Community Version - Irritability (ABC-I) Subscale Score|Percentage of Participants with responder status of "Very Much Improved" or "Much Improved" on the Clinical Global Impression- Change Irritability (CGI-C Irritability) Scale|Change from Baseline in Parent-Rated Anxiety Scale for Youth with Autism Spectrum Disorder (PRAS-ASD) Total Score|Change from Baseline in Caregiver Strain Questionnaire Short Form 7-Item (CGSQ SF-7) total score	AbbVie	All	5 Years to 17 Years   (Child)	Phase 3	152	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	M21-465	July 7, 2022	May 24, 2024	September 8, 2024	June 30, 2022		December 14, 2022	Advanced Research Center /ID# 245049, Anaheim, California, United States|Sun Valley Research Center /ID# 243133, Imperial, California, United States|CHOC Children's Hospital /ID# 245577, Orange, California, United States|Sarkis Clinical Trials /ID# 242868, Gainesville, Florida, United States|Advanced Research Institute of Miami /ID# 243179, Homestead, Florida, United States|Sandhill Research LLC /ID# 245079, Lake Mary, Florida, United States|Axcess Medical Research /ID# 244952, Loxahatchee Groves, Florida, United States|K2 Medical Research /ID# 248694, Maitland, Florida, United States|Medical Research Group of Central Florida /ID# 243170, Orange City, Florida, United States|APG Research, LLC /ID# 243130, Orlando, Florida, United States|Nona Pediatric Center /ID# 245078, Orlando, Florida, United States|Asclepes Research Centers - Spring Hill /ID# 248682, Spring Hill, Florida, United States|D&H Tamarac Research Center /ID# 250436, Tamarac, Florida, United States|Atlanta Center for Medical Research /ID# 243124, Atlanta, Georgia, United States|Atlanta Behavioral Research, LLC /ID# 243082, Dunwoody, Georgia, United States|Baber Research Group /ID# 242998, Naperville, Illinois, United States|New Dawn Psychiatric Services PLLC /ID# 243697, Kinston, North Carolina, United States|Cincinnati Children's Hospital /ID# 243968, Cincinnati, Ohio, United States|CincyScience /ID# 242993, West Chester, Ohio, United States|Relaro Medical Trials /ID# 243126, Dallas, Texas, United States|Cedar Health Research /ID# 248683, Dallas, Texas, United States|AIM Trials /ID# 243120, Plano, Texas, United States|Family Psychiatry of The Woodlands /ID# 242867, The Woodlands, Texas, United States|Advanced Research Institute - Ridgeline /ID# 243098, Ogden, Utah, United States|Office of Maria Ona /ID# 248149, Franklin, Virginia, United States|Core Clinical Research /ID# 243084, Everett, Washington, United States|Multicare Institute for Research and Innovation /ID# 245153, Tacoma, Washington, United States|Dr. Samuel Sanchez PSC /ID# 245739, Caguas, Puerto Rico|GCM Medical Group PSC /ID# 245735, San Juan, Puerto Rico|BDH Research /ID# 251050, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT05439616
28	NCT05626959	Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder		Not yet recruiting	No Results Available	Autism Spectrum Disorder	Drug: NTI164	Change in Clinical Global Impression-Severity (CGI-S)|Vineland Adaptive Behaviour Scales, Third Edition|Social Responsiveness Scale, 2nd Editions (SRS-2)|Clinical Global Impression Scale - Improvement (CGI-I)|Anxiety, Depression and Mood Scale (ADAMS)|Sleep Disturbance Scale for Children (SDSC)|Anxiety Scale for Children - Autism Spectrum Disorder|Caregiver Global Impression of Change in Attention (CGI-CA)|Caregiver Global Impression of Change (CGI-C) Target Behaviour	Fenix Innovation Group|Neurotech International|Monash Health	All	8 Years to 17 Years   (Child)	Phase 2|Phase 3	54	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	NTIASD2	November 30, 2022	March 1, 2023	November 30, 2023	November 25, 2022		November 25, 2022	Monash Children's Hospital, Clayton, Victoria, Australia		https://ClinicalTrials.gov/show/NCT05626959
29	NCT05516407	Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.		Active, not recruiting	No Results Available	Autism Spectrum Disorder	Drug: FEN164	Clinical Global Impression Scale - Improvement (CGI-I)|Vineland Adaptive Behaviour Scales, Third Edition|Social Responsiveness Scale, 2nd Editions (SRS-2)|Anxiety, Depression and Mood Scale (ADAMS)|Sleep Disturbance Scale for Children (SDSC)|Clinical Global Impression-Severity (CGI-S)|Autism Family Experience Questionnaire (AFEQ)|Anxiety Scale for Children - Autism Spectrum Disorder - Parent Version (ASC-ASD-P)|Anxiety Scale for Children - Autism Spectrum Disorder - Child Version (ASC-ASD-C)|The Child Behaviour Checklist for Ages 6 - 18 (CBCL)|Caregiver Global Impression of Change in Attention (CGI-CA)|Caregiver Global Impression of Change (CGI-C) Target Behaviour	Fenix Innovation Group|Neurotech International|Monash Health	All	8 Years to 17 Years   (Child)	Phase 1|Phase 2	18	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FNX001-21	April 1, 2021	September 1, 2022	September 2, 2022	August 25, 2022		August 25, 2022	Monash Children's Hospital, Clayton, Victoria, Australia		https://ClinicalTrials.gov/show/NCT05516407
30	NCT03672344	Computer-based Social Skills Training for Autism Spectrum Disorder		Completed	Has Results	Autism Spectrum Disorder	Device: Lookware TM|Device: Lookware TM Control Module	Ekman-60 Faces Test|Social Responsiveness Scale|Childhood Joint Attention Rating Scale	BioStream Technologies, LLC	All	4 Years to 14 Years   (Child)	Not Applicable	54	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	08012018A	August 25, 2018	February 19, 2020	February 19, 2020	September 14, 2018	July 15, 2022	July 15, 2022	Milestones Behavioral Services, Orange, Connecticut, United States|Els for Autism Foundation, Jupiter, Florida, United States|Positive Behavior Supports Corporation, Melbourne, Florida, United States|Positive Behavior Supports Corporation, Miami, Florida, United States|Positive Behavior Supports Corporation, West Palm Beach, Florida, United States|Nashoba Learning Group, Inc., Bedford, Massachusetts, United States|Y.A.L.E. School, Cherry Hill, New Jersey, United States|Connect Plus Therapy, Inc., Cherry Hill, New Jersey, United States|Partners in Learning, Inc., Clementon, New Jersey, United States|Mary E. Keefe, Point Pleasant Beach, New Jersey, United States|The Pathway School, Jeffersonville, Pennsylvania, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03672344/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03672344
31	NCT05523895	Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder		Recruiting	No Results Available	Irritability Associated With Autism Spectrum Disorder	Drug: Pimavanserin|Drug: Placebo	Change from Baseline at Week 6 in caregiver-rated Aberrant Behavior Checklist (ABC) Irritability subscale score|Change from Baseline at Week 6 in caregiver-rated ABC subscale scores: Stereotypic Behavior; Lethargy; Hyperactivity; Inappropriate speech|Change from Baseline at Week 6 in Clinical Global Impression-Severity (CGI-S) of Irritability score|Clinical Global Impression-Improvement (CGI-I) of irritability score at Week 6|Change from Baseline at Week 6 in Repetitive Behavior Scale-Revised (RBS-R) scores|Change from Baseline at Week 6 in Vineland Adaptive Behavior Scales (VABS)-Socialization subscale score|Change from Baseline at Week 6 in Caregiver Strain Questionnaire (CGSQ) scores|Proportion of patients with at least 25% reduction from Baseline in ABC-Irritability subscale score at Week 6|Proportion of patients with CGI-I of irritability score of 1 (very much improved) or 2 (much improved) at Week 6|Proportion of patients with at least 25% reduction from Baseline in ABC-Irritability subscale score and CGI-I of irritability score of 1 or 2 at Week 6	ACADIA Pharmaceuticals Inc.	All	5 Years to 17 Years   (Child)	Phase 2|Phase 3	228	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ACP-103-069	August 9, 2022	June 2024	June 2024	August 31, 2022		December 7, 2022	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Cortica Inc. (San Rafael), San Rafael, California, United States|Cortica Inc. (Westlake), Westlake Village, California, United States|1st Allergy and Clinical Research Group, d/b/a IMUNOe Research Centers, Centennial, Colorado, United States|Children's Research Institute, Washington, District of Columbia, United States|The EHS Medical Practice, PA, D/B/A Sarkis Clinical Trials, Gainesville, Florida, United States|APG Research, LLC, Orlando, Florida, United States|AMR Baber Research Incorporated, Naperville, Illinois, United States|Neurobehavorial Medical Group, Bloomfield Hills, Michigan, United States|Clinical Research of Southern Nevada, LLC, Las Vegas, Nevada, United States|ERG Clinical Research - New York, PLLC DBA Richmond Behavioral Associates, Staten Island, New York, United States|Quest Therapeutics of Avon Lake dba Haidar Almhana Nieding LLC, Avon Lake, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Cedar Clinical Research, Draper, Utah, United States|Eastside Therapeutic Resource, Inc. dba Core Clinical Research, Everett, Washington, United States|CHU de Nantes, Nantes, France|Vadaskert Hospital, Budapest, Hungary|Ginemedica Sp. Zoo, S.K., Wrocław, Poland|Medic Mental Indywidualna Specjalistyczna Praktyka Lekarska, Wrocław, Poland|Hospital General Universitario de Alicante, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT05523895
32	NCT03849456	Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder		Terminated	No Results Available	Autism Spectrum Disorder	Drug: GWP42006	Number of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)|Change from Baseline in Children's Communication Checklist-2 (CCC-2)|Change from Baseline in Social Responsiveness Scale-2 (SRS-2)|Change from Baseline in Vineland Adaptive Behavior Scales, 3rd Edition (Vineland-3)|Change from Baseline in National Institutes of Health (NIH) Toolbox Cognition Battery|Change from Baseline in Repetitive Behavioral Scale - Revised (RBS-R)|Change from Baseline in Children's Sleep Habits Questionnaire (CSHQ)|Change from Baseline in Aberrant Behavior Checklist (ABC)|Clinical Global Impressions-Improvement (CGI-Improvement)	Jazz Pharmaceuticals	All	4 Years to 18 Years   (Child, Adult)	Phase 2	1	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GWND18089	January 7, 2020	May 26, 2020	May 26, 2020	February 21, 2019		September 2, 2022	Clinical Trial Site, Louisville, Kentucky, United States|Clinical Trial Site, Lexington, Massachusetts, United States|Clinical Trial Site, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03849456
33	NCT04745026	Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder		Recruiting	No Results Available	Autism Spectrum Disorder	Drug: GWP42003-P|Drug: Placebo	Change from Screening in Aberrant Behavior Checklist (ABC) Subscale Scores|Change from Day 1 in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores|Change from Day 29 in Clinical Global Impression Improvement (CGI-I) Scores|Change from Screening in Clinical Global Impression Severity (CGI-S) Scores|Number of Participants with Severe Treatment-emergent Adverse Events|Number of Participants with Clinically Significant Clinical Laboratory Parameter Values|Number of Participants with Clinically Significant Vital Sign Values|Number of Participants with Clinically Significant Physical Examination Procedure Findings|Number of Participants with Clinically Significant 12-lead Electrocardiogram Findings|Number of Participants with a Positive Response to Questions Regarding Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)	Jazz Pharmaceuticals	All	6 Years to 17 Years   (Child)	Phase 2	160	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	GWND19189|2020-002819-21	May 31, 2021	February 28, 2023	March 30, 2023	February 9, 2021		December 6, 2022	Southwest Autism Research and Resource Center (SARRRC), Phoenix, Arizona, United States|UCLA Neuropsychiatric Institute, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|APG Research, LLC, Orlando, Florida, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital (Lurie Center for Autism), Lexington, Massachusetts, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Seattle Children's Research Institute, Seattle, Washington, United States|Queensland Children's Hospital, South Brisbane, Australia|The Kids Clinic, Ajax, Ontario, Canada|Center for Pediatric Excellence, Ottawa, Ontario, Canada|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Spain|University of Glasgow Institute of Health and Wellbeing, Glasgow, United Kingdom|Institute of Psychiatry, King's College London, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04745026
34	NCT01706523	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders		Terminated	No Results Available	Autism Spectrum Disorders	Drug: STX209 (arbaclofen)	Safety and tolerability of STX209|Aberrant Behavior Checklist	Seaside Therapeutics, Inc.	All	5 Years to 21 Years   (Child, Adult)	Phase 3	165	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	209AS209	November 2011	July 2013	July 2013	October 15, 2012		July 31, 2013	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|UCDavis M.I.N.D Insitute, Sacramento, California, United States|Pharmax Research Clinic, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Institute for Juvenile Research, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|NYS Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States|UNC Chapel Hill Department of Psychiatry, Chapel Hill, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Group, LeBonheur Children's Hospital, Memphis, Tennessee, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01706523
35	NCT04049578	A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder		Terminated	Has Results	Autism Spectrum Disorder	Drug: Balovaptan	Area Under the Curve at Steady State (AUCss) of Balovaptan|Plasma Concentration of Balovaptan|Plasma Concentration of M2 Metabolite, as Applicable|Plasma Concentation of M3 Metabolite|Plasma Concentration Ratio of M2 to Balovaptan, as Applicable|Plasma Concentration Ratio of M3 to Balovaptan|Number of Participants With Adverse Events	Hoffmann-La Roche	All	2 Years to 4 Years   (Child)	Phase 1	2	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WP40877	December 19, 2019	April 23, 2020	May 6, 2020	August 8, 2019	October 14, 2020	October 14, 2020	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University Hospitals Cleveland Medical Center; Division of Child and Adolescent Psychiatry, Cleveland, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04049578/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04049578
36	NCT03504917	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension		Terminated	Has Results	Autism Spectrum Disorder	Drug: Balovaptan|Drug: Placebo	Change From Baseline at Week 24 on the Vineland Adaptive Behavior Scales (Vineland-II) Two-domain Composite (2DC) Score.|Change From Baseline at Week 12 on the Vineland-II 2DC Score|Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores|Change From Baseline at Weeks 12 and 24 in the Vineland-II Adaptive Behavior Composite Standard Score|Change From Baseline at Week 12 and 24 on the Vineland-II Socialization Domain Standard Score|Change From Baseline at Weeks 12 and 24 on the Vineland-II Communication Domain Standard Score|Change From Baseline at Weeks 12 and 24 on the Vineland-II Daily Living Skills Domain Standard Score|Change From Baseline in Severity of Clinical Impressions as Measured by Clinical Global Impression-Severity (CGI-S)|Improvements in Clinical Impressions, as Measured by Clinical Global Impression-Improvement (CGI-I)|Change From Baseline at Weeks 12 and 24 in the Hamilton Anxiety Rating Scale (HAM-A) Total and Domain Scores|Proportion of Subjects With a >=6-point Improvement in Vineland-II 2DC Score|Percentage of Participants With Adverse Events	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 3	322	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	WN39434	August 8, 2018	March 4, 2020	July 1, 2020	April 20, 2018	May 7, 2021	October 27, 2021	Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|University of California , Los Angeles (UCLA); Child, Adolescent Psychiatry, Los Angeles, California, United States|PCSD Feighner Research, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Uni of Chicago; Centre For Advanced Medicine, Chicago, Illinois, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Hapworth Research Inc., New York, New York, United States|Center for Autism and the Developing Brain, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center; Department of Psychiatry, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Seattle Children's Hospital, Seattle, Washington, United States|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|University of Western Ontario, London, Ontario, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, Canada|Hopital Charles Perrens; Centre de Ressources Autisme Aquitaine, Bordeaux, France|Hospices Civils de Lyon; Centre d'Investigation Clinique Pédiatrique, LYON Cedex, France|Centre hospitalier du Rouvray; CRAHN Centre de Ressources Autisme Haute-Normandie, Sotteville Les Rouen, France|ASST di Pavia; Dip. di Scienze del Sistema Nervoso e del Comportamento, Pavia, Lombardia, Italy|AUSL di Piacenza; Psichiatria di Collegamento, Piacenza, Lombardia, Italy|ASL TO2; Centro Pilota Regione Piemonte - Dip. Salute Mentale, Torino, Piemonte, Italy|A.O.U. Policlinico - V. Emanuele - P.O. Gaspare Rodolico; Dip. Terapia integrata disturbi resistenti, Catania, Sicilia, Italy|Hospital Mutua de Terrassa; Departamento de Psiquiatria, Terrassa, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Psiquiatria del niño y del adolescente, Madrid, Spain|Hospital Universitario Rio Hortega; Departamento de Psiquiatria, Valladolid, Spain|Western General Hospital; Wellcome Trust CRF, Edinburgh, United Kingdom|Queen Elizabeth University Hospital; Clinical Research Facility, Glasgow, United Kingdom|Kings College Hospital; Kings Clinical Research Facility, London, United Kingdom|RE:Cognition Health; RE:Cognition Health, London, United Kingdom	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03504917/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03504917
37	NCT03611075	A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)		Completed	Has Results	Autism Spectrum Disorder	Other: No Intervention	Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CY-BOCS-ASD) - Total Score|Montefiore Einstein Rigidity Scale (MERS-R)|Repetitive Behavior Scale-Revised (RBS-R)|Repetitive Behavior Questionnaire for Children (RBQ-2)|Restricted Behavior Questionnaire for Adults (RBQ-2A)|Childhood Routines Inventory-Revised (CRI-R)|Adult Routines Inventory (ARI)|Clinical Global Impression Scales (CGI)|Child's Sleep Habits Questionnaire (CSHQ)|Pittsburg Sleep Quality Index (PSQI)|Reading the Mind in the Eyes Test -R (RMET-R)|Reading the Mind in the Eyes Test Child -C (RMET-C)|Hamilton Anxiety Rating Scale (HAM-A)|Parent Rated Anxiety Scale for ASD (PRAS-ASD)|Beck Anxiety Index (BAI)|Digital Biomarkers|Behaviour Rating Inventory of Executive Function for Children (BRIEF)|Behaviour Rating Inventory of Executive Function for Adults (BRIEF-A)|Short Sensory Profile (SSP)|Vineland(TM)-II Survey|Pediatric Quality of Life Inventory (PedsQL) Family Impact Scale|PedsQL Core Functioning Scale|PedsQL Cognitive Functioning Scale	Hoffmann-La Roche	All	5 Years to 45 Years   (Child, Adult)	Phase 1	144	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	BP40331|2019-003524-20	August 13, 2018	May 21, 2020	May 21, 2020	August 2, 2018	July 23, 2021	June 21, 2022	Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|PCSD Feighner Research, San Diego, California, United States|Stanford University School of Medicine, Stanford, California, United States|Clinical Neuroscience Solutions Inc; Jacksonville Clinic, Jacksonville, Florida, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research Ltd, San Antonio, Texas, United States|Northwest Clinical Research Center - ClinEdge - PPDS, Bellevue, Washington, United States|Seattle Children's Hospital - PIN; Investigational Drug Services, Seattle, Washington, United States|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|Gartnavel Royal Hospital; Mental Health & Wellbeing, Glasgow, United Kingdom|Kings College London, London, United Kingdom	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03611075/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03611075
38	NCT03664232	A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder	Envision	Completed	No Results Available	Autism Spectrum Disorder	Drug: JNJ-42165279|Drug: Placebo	Change from Baseline in the Autism Behavior Inventory (ABI) Core Domain Score to Day 85|Change from Baseline in ABI Social Communication Domain Score to Day 85|Change from Baseline in ABI Repetitive/Restrictive Behavior (RRB) Domain Score to Day 85|Change from Baseline in the ABI Mood and Anxiety Domain Score to Day 85|Change from Baseline in the ABI Challenging Behavior Domain Score|Change from Baseline in the ABI Self-Regulation Domain Score|Change from Baseline in the Aberrant Behavior Checklist (ABC) Subscales|Change from Baseline in the Autism Behavior Inventory-Short Form (ABI-S) Scale Domains|Change from Baseline in the Autism Behavior Inventory-Clinician Interview (ABI-C) Domains|Change from Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score|Change from Baseline in the Repetitive Behavior Scale - Revised (RBS-R) Scale Score|Change from Baseline in the Zarit Burden Interview (ZBI) Scale Score|Change from Baseline in the Child Adolescent Symptom Inventory - Anxiety (CASI-Anx) Scale Score|Change from Baseline in the Social Responsiveness Scale 2 (SRS-2) Score|Change from Baseline in the Caregiver Global Impression of Severity (Caregiver GI-S)|Caregiver Assessment of Treatment Score|Self Global Impression of Improvement (Self GI-I) Score|Clinical Global Impression-Improvement (CGI-I)	Janssen Research & Development, LLC	All	13 Years to 35 Years   (Child, Adult)	Phase 2	78	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CR108275|42165279AUT2001	November 7, 2018	October 17, 2022	October 28, 2022	September 10, 2018		December 8, 2022	Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|NRC Research Institute, Orange, California, United States|New York Presbyterian Hospital, New York, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03664232
39	NCT01985308	A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism		Completed	No Results Available	Autism Spectrum Disorder	Device: MRT-Active|Device: MRT-SHAM	Childhood Autism Rating Scale (CARS)	Wave Neuroscience	All	4 Years to 12 Years   (Child)	Not Applicable	28	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	MRT-001	November 2013	April 2014	April 2014	November 15, 2013		April 16, 2014	Brain Treatment Center, Newport Beach, California, United States|Brain Treatment Center of Atlanta, Buford, Georgia, United States		https://ClinicalTrials.gov/show/NCT01985308
40	NCT02901431	A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)		Terminated	Has Results	Autism Spectrum Disorder	Drug: Placebo|Drug: RO5285119	Change From Baseline in Vineland™-II Adaptive Behavior Scale Two Domain Composite (2DC) Score at Week 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland™-II Composite Standard Score After 12 Weeks and 24 Weeks of Treatment for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland™-II Adaptive Behavior Scale Communication, Socialization, and Daily Living Skills Domain Standard Scores at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Proportion of Subjects With >=6 Points Improvement in the Vineland-II 2DC Score for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Ohio Autism Clinical Impressions Scale-Severity (OACIS-S) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Clinical Global Impressions- Improvement (CGI-I) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Ohio Autism Clinical Impressions Scale- Improvement (OACIS-I) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Patient-Reported Pediatric Quality of Life (PedsQL) v4.0 Generic Core Scale After 12 Weeks and 24 Weeks of Treatment for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland-II Composite Standard Score in Adolescents and Children Independently at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland-II Adaptive Behavior Scale 2DC Score at Week 12 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Percentage of Participants With Adverse Events for Treatment With Balovaptan	Hoffmann-La Roche	All	5 Years to 17 Years   (Child)	Phase 2	339	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BP30153	November 21, 2016	April 15, 2020	June 30, 2020	September 15, 2016	February 8, 2021	February 8, 2021	Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|NRC Research Institute, Orange, California, United States|PCSD Feighner Research, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital of Colorado, Aurora, Colorado, United States|DBA IMMUNOe Int'l Res Center, Centennial, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Segal trials, North Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|USF Rothman Center, Saint Petersburg, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital; Lurie Center for Autism, Lexington, Massachusetts, United States|UMASS Medical School, Worcester, Massachusetts, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Midwest Childrens Health Research Institute, Lincoln, Nebraska, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Center for Autism and the Developing Brain, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|DUKE SCHOOL OF MEDICINE;Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia;Allergy/Immunology Department, Philadelphia, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Core Clinical Research, Everett, Washington, United States|Seattle Children's Research Institute; Psychiatry and Behavioral Medicine, Seattle, Washington, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02901431/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02901431/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02901431
41	NCT04895215	AB-2004 in Treatment of Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD)		Recruiting	No Results Available	Autism Spectrum Disorder (ASD)	Drug: AB-2004|Drug: Placebo	The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 High Dose|The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 Low Dose|The mean change in the Clinical Global Impression-Severity (CGI-S) from Baseline to Week 8 for AB-2004 High Dose and AB-2004 Low Dose|Number of participants who reported treatment emergent adverse events (TEAEs)	Axial Therapeutics, Inc.	All	13 Years to 17 Years   (Child)	Phase 2	195	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	AXL-2004-002	August 2, 2021	December 2022	June 2023	May 20, 2021		August 18, 2022	Southwestern Autism Research and Resource Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, Davis-MIND Institute, Sacramento, California, United States|University of California, San Francisco, California, United States|Cortica Marin, San Rafael, California, United States|Michael Purdy, Westlake Village, California, United States|Yale University, New Haven, Connecticut, United States|CNS Solutions, Jacksonville, Florida, United States|CNS Solutions, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Baber Research, Naperville, Illinois, United States|LSU Health- Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Lurie Center, Lexington, Massachusetts, United States|Catherine Masters, Bloomfield Hills, Michigan, United States|Clinical Research of Southern Nevada, Las Vegas, Nevada, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|jasmine Sanders, Columbus, Ohio, United States|Carilion Medical Center, Roanoke, Virginia, United States|Murdoch Children's Research Institute, Parkville, Victoria, Australia|Children's Health Queensland Hospital, South Brisbane, Australia|Westmead Children's Hospital, Sydney, Australia|Optimal Clinical Trials, Auckland, New Zealand		https://ClinicalTrials.gov/show/NCT04895215
42	NCT05182697	SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)		Not yet recruiting	No Results Available	Autism Spectrum Disorder (ASD)	Drug: SCI-210|Drug: Oral CBD oil	Evaluation of the safety of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)|Evaluation of the efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)|Evaluate the safety of SCI-210 in children with ASD.|Evaluate the tolerability of SCI-210 in children with ASD.|Assess the efficacy of SCI-210 in reducing disruptive behaviors among children with ASD|Assess the efficacy of SCI-210 in reducing sleep problems among children with ASD|Assess the efficacy of SCI-210 in reducing ASD symptoms among children with ASD.|Assess the efficacy of SCI-210 in improving adaptive behaviors among children with ASD|Assess the efficacy of SCI-210 in improving language abilities among children with ASD|Assess the effects of SCI-210 on eye tracking measures when viewing social movies.	SciSparc|Negev Autism Center Soroka University Medical Center	All	5 Years to 18 Years   (Child, Adult)	Not Applicable	60	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SCRC21013	October 2022	June 2024	December 2024	January 10, 2022		May 5, 2022	Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, Israel, Be'er-Sheva, Israel		https://ClinicalTrials.gov/show/NCT05182697
43	NCT05413187	A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder		Withdrawn	No Results Available	Autistic Disorder	Drug: Medical Grade Cannabis oil|Drug: Placebos	change in symptoms of Autism spectrum disorder|change in score of The Clinical Global Impressions-Improvement (CGI-I)|change in score of Sensory Profile II (SP-2)|Changes in eye movements|Changes in the sleep architecture (optional)	TO Pharmaceuticals	All	2 Years to 8 Years   (Child)	Phase 2	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SCRC17039	September 1, 2020	September 1, 2022	September 1, 2022	June 9, 2022		June 9, 2022	Soroka University Medical Center, Beer Sheva, Israel		https://ClinicalTrials.gov/show/NCT05413187
44	NCT00846547	Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders		Completed	Has Results	Autism Spectrum Disorders	Drug: Arbaclofen	Irritability Subscale of the Aberrant Behavior Checklist, Community Version	Seaside Therapeutics, Inc.	All	6 Years to 17 Years   (Child)	Phase 2	32	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	22003	February 2009	June 2010	September 2010	February 18, 2009	June 14, 2013	June 14, 2013	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, PA, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00846547
45	NCT02414503	Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder		Completed	No Results Available	Autism Spectrum Disorder	Drug: 8IU intranasal oxytocin|Drug: 24IU intranasal oxytocin|Drug: Placebo|Device: OptiNose Breath Powered Bi	Performance on an emotion sensitivity test|Performance on a facial emotion morphing task|Performance on the reading the mind in the eyes test|Performance on an emotional dot probe task|Heart rate variability|Eyetracking	OptiNose AS|Oslo University Hospital|University of Oslo	Male	18 Years to 35 Years   (Adult)	Phase 1|Phase 2	17	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	SMR-2728|2014-005452-26	April 2015	February 2016	February 2016	April 10, 2015		September 27, 2016	NORMENT, KG Jebsen Centre for Psychosis Research - TOP Study, Oslo, Norway		https://ClinicalTrials.gov/show/NCT02414503
46	NCT02226458	An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder	Autism	Withdrawn	No Results Available	Autism Spectrum Disorder	Drug: EPI-743	Primary Efficacy|Secondary Endpoint|Safety Endpoint	Edison Pharmaceuticals Inc	All	3 Years to 14 Years   (Child)	Phase 2	0	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EPI743-14-025	October 31, 2014	November 30, 2015	January 31, 2016	August 27, 2014		January 21, 2022			https://ClinicalTrials.gov/show/NCT02226458
47	NCT04299464	A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)		Recruiting	No Results Available	Autism Spectrum Disorder (ASD)	Drug: Placebo|Drug: RO7017773	Change from Baseline to Week 12 in the Adaptive Behavior Composite score of the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3)|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants Discontinuing Treatment due to AEs|Change from Baseline Over Time in Suicide Risk Using the Columbia-Suicide-Severity Rating Scale (C-SSRS)|Change from Baseline to Week 12 in Behavior/Symptoms as Measured by all Domains of the Repetitive Behavior Scale-Revised (RBS-R)|Change from Baseline to Week 12 on the Vineland-3 Socialization Domain|Change from baseline to Week 12 on the Vineland-3 Communication domains	Hoffmann-La Roche	All	15 Years to 45 Years   (Child, Adult)	Phase 2	105	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BP41316|2019-003524-20	March 31, 2021	September 30, 2023	September 30, 2023	March 6, 2020		December 7, 2022	Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California at San Francisco, San Francisco, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Massachusetts General Hospital; Lurie Center for Autism, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Core Clinical Research, Kirkland, Washington, United States|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Janeway Childrens Health; and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|AOU Policlinico Tor Vergata, Università Roma Tor Vergata, Roma, Lazio, Italy|Ist. G. Gaslini; UOC Neuropsichiatria Infantile, Genova, Liguria, Italy|Istituto Scientifico Medea; U.O Psicopatologia età evolutiva, Bosisio Parini (LC), Lombardia, Italy|ASST di Pavia; Dip. di Scienze del Sistema Nervoso e del Comportamento, Pavia, Lombardia, Italy|P.O. Gaspare Rodolico; UOC Clinica Psichiatrica, Catania, Sicilia, Italy|IRCCS Fondazione Stella Maris; U.O. Complessa NPI 3 - Psichiatria dello sviluppo, Calambrone (PI), Toscana, Italy|Hospital Santa Caterina; Servicio de Psiquiatría, Salt, Girona, Spain|IGAIN (Instituto Global de Atención Integral al Neurodesarrollo), Barcelona, Spain|Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría, Barcelona, Spain|Hospital Universitario Infanta Leonor; Servicio de Psiquiatría, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04299464
48	NCT01793441	A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)		Completed	No Results Available	Autism Spectrum Disorder	Drug: Placebo|Drug: RG7314	Change From Baseline in Social Communication Deficits as Measured by Social Responsiveness Scale 2 (SRS-2)|Percentage of Participants with Suicidality, as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants With Adverse Events|Change From Baseline in Behavior/Symptoms as Measured by Aberrant Behavior Checklist (ABC)|Change From Baseline in Behavior/Symptoms as Measured by Repetitive Behavior Scale-Revised (RBS-R)|Change From Baseline in Behavior/Symptoms as Measured by Anxiety, Depression and Mood Scale (ADAMS)|Measure: Change From Baseline in Behavior/Symptoms as Measured by State-Trait Anxiety Inventory (STAI)|Change From Baseline in Clinical Global Impressions as Measured by Clinical Global Impressions Improvement (CGI-I) Scale|Change From Baseline in Adaptive Functioning and Skills as Measured by Vineland-II Adaptive Behavior Scale (VABS)|Plasma Concentration of RG7314|Plasma Concentration of RG7314 Metabolite M3|Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Concentration (AUClast) of RG7314|AUClast of RG7314 Metabolite M3|Maximum Observed Plasma Concentration (Cmax) of RG7314|Cmax of RG7314 Metabolite M3|Percentage of Participants With Clinical Response, Defined as At Least 25% Improvement in the SRS-2 Score With a CGI-I Score of 1 or 2	Hoffmann-La Roche	Male	18 Years to 45 Years   (Adult)	Phase 2	223	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BP28420|2012-005597-55	September 2013	September 2016	September 2016	February 15, 2013		February 3, 2017	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|Sacramento, California, United States|PCSD Feighner Research, San Diego, California, United States|San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Stanford, California, United States|DBA IMMUNOe Int'l Res Center, Centennial, Colorado, United States|Centennial, Colorado, United States|Yale University; Yale Child Study Center, New Haven, Connecticut, United States|New Haven, Connecticut, United States|Neurology offices of south florida, Delray Beach, Florida, United States|Delray Beach, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Oakland Park, Florida, United States|Compass Research, Orlando, Florida, United States|Orlando, Florida, United States|Emory University School of Medicine; Department of Human Genetics & Pediatrics, Decatur, Georgia, United States|Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Chicago, Illinois, United States|The Kennedy Krieger Institute, Baltimore, Maryland, United States|Baltimore, Maryland, United States|Neuroscientific Insights, Rockville, Maryland, United States|Rockville, Maryland, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|Lexington, Massachusetts, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|Montefiore Medical Center; Departments of Psychiatry & Biobehavioral Science, Bronx, New York, United States|Bronx, New York, United States|Mount Sinai School of Medicine; Seaver Autism Center, New York, New York, United States|New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Orangeburg, New York, United States|DUKE SCHOOL OF MEDICINE;Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Cleveland, Ohio, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|Nashville, Tennessee, United States|Road Runner Research, San Antonio, Texas, United States|San Antonio, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Bothell, Washington, United States|Seattle Children's Research Institute, Seattle, Washington, United States|Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01793441
49	NCT02708069	e-Unstuck:Interactive e-Learning Software for Parents to Support Executive Functioning and Behavior Regulation in Children With Autism Spectrum Disorder	e-Unstuck	Completed	No Results Available	Autistic Disorder	Other: e-Unstuck|Other: Unstuck and On Target	Change from baseline in ratings of top three child EF difficulties interference with daily functioning as measured on the Top Executive Functioning Difficulties.|Change from baseline in child executive function using the Behavior Rating of Executive Function-II (BRIEF-II).|Change from baseline in parental self-efficacy on the Parenting Sense of Competence Scale.|Change from Baseline in parental perceptions of caregiving as measured on the Caregiver Questionnaire	3-C Institute for Social Development|Children's National Health System	All	Child, Adult, Older Adult	Not Applicable	97	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	1R44MH109193	March 1, 2017	February 28, 2018	February 28, 2018	March 15, 2016		July 31, 2018	Children's National Health System, Rockville, Maryland, United States|3C Institute, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02708069
50	NCT05555615	Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder		Recruiting	No Results Available	Irritability Associated With Autism Spectrum Disorder	Drug: Pimavanserin	Treatment-emergent adverse events|Evaluate the continued response to long-term pimavanserin treatment in children and adolescents with irritability associated with ASD, defined by a composite endpoint of ABC-I and CGI-I response.	ACADIA Pharmaceuticals Inc.	All	5 Years to 18 Years   (Child, Adult)	Phase 2|Phase 3	228	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACP-103-070	November 2, 2022	July 2025	July 2025	September 27, 2022		December 7, 2022	Cortica Inc., San Rafael, California, United States|Clinical Research of Southern Nevada, LLC, Las Vegas, Nevada, United States		https://ClinicalTrials.gov/show/NCT05555615
51	NCT00337571	Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)		Completed	Has Results	Behavioral Symptoms|Autistic Disorder	Drug: Aripiprazole|Drug: Placebo	Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score|Mean Clinical Global Impressions Improvement Scale (CGI-I) Score|Number of Participants With Response at Week 8|Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)|Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores|Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)|Summary of Safety|Change From Baseline in Body Weight	Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical	All	6 Years to 17 Years   (Child)	Phase 3	218	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CN138-179	June 2006	June 2008	June 2008	June 16, 2006	July 23, 2009	December 2, 2013	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience, Dothan, Alabama, United States|Southwest Autism Research And Resource Center, Phoenix, Arizona, United States|Clinical Innovations, Inc., Huntington Beach, California, United States|University Of California-Davis Medical Center, Sacramento, California, United States|Stanford University School Of Medicine, Stanford, California, United States|The Children'S Hospital, Aurora, Colorado, United States|Marsella, Gregory, Boca Raton, Florida, United States|University Of Florida, Gainesville, Florida, United States|University Of South Florida, Tampa, Florida, United States|Institute For Behavioral Medicine, Smyrna, Georgia, United States|University Of Illinois At Chicago, Chicago, Illinois, United States|Cambridge Health Alliance, Medford, Massachusetts, United States|Ladders Clinic, Wellsley, Massachusetts, United States|Children'S Hospital Of Michigan, Detroit, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Children'S Mercy Hospital, Kansas City, Missouri, United States|Munroe-Meyer Institute, Omaha, Nebraska, United States|North Shore - Long Island Jewish Health System, Bethpage, New York, United States|Seaver And New York Autism Center Of Excellence, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Mission Hospitals, Asheville, North Carolina, United States|Duke Child And Family Study Center, Durham, North Carolina, United States|The Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Western Psychiatric Institute And Clinic, Pittsburgh, Pennsylvania, United States|Dallas Pediatric Neurology Associates, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Children'S National Medical Center, Fairfax, Virginia, United States|Pacific Institute Of Medical Sciences, Bothell, Washington, United States|Children'S Hospital Of Wisconsin, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00337571
52	NCT04382885	Cariprazine Pediatric ASD PK Study		Completed	No Results Available	Autism Spectrum Disorder	Drug: Cariprazine	Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Percentage of participants with potentially clinically significant values in clinical laboratory assessments|Percentage of participants with potentially clinically significant values in vital signs assessments|Percentage of participants with potentially clinically significant values in ECG assessments|Percentage of participants who have suicidal ideation or suicidal behaviors in C-SSRS assessments|Percentage of participants with treatment-emergent parkinsonism in SAS assessments|Percentage of participants with treatment-emergent akathisia in BARS assessments|Percentage of participants with potentially clinically significant values in ocular examination parameters|Pharmacokinetics: Maximum plasma concentrations (Cmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Area under the plasma concentration-time curve during the dosing interval (AUC0-tau) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Terminal elimination half-life (T1/2) of cariprazine and its metabolites DCAR and DDCAR|Pharmacokinetics: Minimum plasma concentrations (Cmin) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42|Pharmacokinetics: Average plasma concentrations (Cavg) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42|Pharmacokinetics: Apparent total clearance of cariprazine from plasma (CL/F) on Day 42|Pharmacokinetics: Volume of distribution during the terminal elimination phase (Vz/F) of cariprazine	AbbVie	All	5 Years to 17 Years   (Child)	Phase 1	24	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000-103-009	June 26, 2020	December 10, 2021	December 10, 2021	May 11, 2020		April 12, 2022	Neuropsychiatric Research Center of Orange County /ID# 233663, Orange, California, United States|Atlanta Center for Medical Research /ID# 233576, Atlanta, Georgia, United States|iResearch Atlanta, LLC /ID# 233614, Decatur, Georgia, United States		https://ClinicalTrials.gov/show/NCT04382885
53	NCT00515320	Study of Fluoxetine in Autism	SOFIA	Completed	No Results Available	Autistic Disorder	Drug: Fluoxetine|Drug: Placebo	The percentage change from baseline to the endpoint visit for the CYBOCS-PDD score.|The time and dose related course of therapeutic effects|The inter-relationship between these effects in the context of global clinical changes.|The indirect effects on patient caregivers of the dose regime in these subjects compared to placebo during treatment.|Safety measures will be physical examination, vital signs, EKG/ECG & clinical laboratory tests.	Neuropharm|Autism Speaks	All	5 Years to 17 Years   (Child)	Phase 3	158	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NPL-2008-4-AUTUS-004	August 2007	January 2009	January 2009	August 13, 2007		April 27, 2012	Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|University of Florida, Department of Psychiatry, Gainesville, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois, Chicago, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Harvard Medical School, Medford, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States|CRCNJ, Voorhees, New Jersey, United States|Long Island Jewish Hospital, Bethpage, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Western Psychiatric Institute and Clinic/ Merck Child Outpatient Clinic, Pittsburgh, Pennsylvania, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Seattle Children's Hosptial University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00515320
54	NCT00576732	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder		Completed	Has Results	Autistic Disorder|Autism	Drug: Placebo|Drug: Risperidone high dose|Drug: Risperidone low dose	Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale|Number of Participants Who Had at Least 25% Improvement in ABC-I|Change in Clinical Global Impression Severity (CGI-S)|Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.|Change in Fasting Glucose (mg/dL) at 6 Weeks|Change in Insulin Resistance (IR) at 6 Weeks|Change in Fasting Glucose (mg/dL) at 6 Months|Change in Insulin Resistance (IR) at 6 Months	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	5 Years to 17 Years   (Child)	Phase 4	96	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CR014740|RISAUT4002	December 2007	September 2009	March 2010	December 19, 2007	September 28, 2010	May 9, 2014	Dothan, Alabama, United States|Phoenix, Arizona, United States|Sacramento, California, United States|Santa Ana, California, United States|Boca Raton, Florida, United States|Miami, Florida, United States|Smyrna, Georgia, United States|Hoffman Estates, Illinois, United States|Naperville, Illinois, United States|Lake Charles, Louisiana, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|Staten Island, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Fairfax, Virginia, United States|Portsmouth, Virginia, United States		https://ClinicalTrials.gov/show/NCT00576732
55	NCT00365859	Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)		Completed	Has Results	Autistic Disorder|Behavioral Symptoms	Drug: Aripiprazole	Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs|Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint|Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities|Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities|Number of Potentially Clinically Relevant Vital Sign Abnormalities|Mean Change From Baseline in Patient Weight|Mean Change From Baseline by Time Period in Body Weight Z-Score|Mean Change From Baseline in Patient Body Mass Index (BMI)|Mean Change From Baseline By Time Period in BMI Z-Score|Mean Change From Baseline in Clinical Global Impression (CGI)-Severity Score at Week 52 (Endpoint, LOCF)|CGI-Improvement Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Hyperactivity Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in ABC Stereotypy Subscale Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Social Withdrawal Scale At Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Inappropriate Speech Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Score at Week 52 (Endpoint, LOCF)	Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical	All	6 Years to 17 Years   (Child)	Phase 3	330	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CN138-180	September 2006	June 2009	June 2009	August 18, 2006	January 25, 2010	December 2, 2013	University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience, Dothan, Alabama, United States|Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|Univ of Arizona, Tuscon, Arizona, United States|Clinical Innovations, Inc, Costa Mesa, California, United States|Peninsula Research Assoc, Rolling Hills Estate, California, United States|University Of California-Davis Health Science Center, Sacramento, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Stanford University School Of Medicine, Stanford, California, United States|The Children's Hospital, Aurora, Colorado, United States|Offices of Gregory Marsella, MD, PA, Boca Raton, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Children's Developmental Center, Winter Park, Florida, United States|Child Neurology Associates, PC, Atlanta, Georgia, United States|Institute For Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Kansas University Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Massachusetts General Hospital, Cambridge, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Ladders Clinic, Wellsley, Massachusetts, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Children's Hospital Of Michigan, Detroit, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Munroe-Meyer Institute Diagnostic Center, Omaha, Nebraska, United States|Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States|Children's Specialized Hospital, Toms River, New Jersey, United States|North Shore - Long Island Jewish Health System, Bethpage, New York, United States|Seaver and New York Autism Center of Excellence, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|SUNY at Stony Brook - School of Medicine, Stony Brook, New York, United States|Mission Hospitals - Mission Children's Clinics, Asheville, North Carolina, United States|University of NC, Chapel Hill, North Carolina, United States|Duke Child and Family Study Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|UT Medical Group, Department Of Psychiatry, Memphis, Tennessee, United States|Dallas Pediatric Neurology Associates, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|North San Antonio Healthcare Associates, San Antonio, Texas, United States|Children's National Medical Center, Fairfax, Virginia, United States|Neuroscience, Inc, Herndon, Virginia, United States|Monarch Research Associates, Norfolk, Virginia, United States|Virginia Treatment Center For Children, Richmond, Virginia, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Autism Spectrum Treatment and Research Center, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00365859
56	NCT00054730	Effects of CX516 on Functioning in Fragile X Syndrome and Autism		Completed	No Results Available	Fragile X Syndrome|Autism	Drug: CX516 (Ampalex®)		RespireRx|FRAXA Research Foundation	All	18 Years to 50 Years   (Adult)	Phase 2		Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	CORX-CX516-013	June 2002			February 11, 2003		June 24, 2005	UC Davis-MIND Institute, Sacramento, California, United States|RUSH-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT00054730
57	NCT00549562	Study of Paliperidone ER in Adolescents and Young Adults With Autism		Completed	Has Results	Autism	Drug: Paliperidone ER	The Clinical Global Impression-Improvement(CGI-I)|The Aberrant Behavior Checklist|The Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders|The Social Responsiveness Scale|The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior Domain	Indiana University School of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC|Indiana University	All	12 Years to 21 Years   (Child, Adult)	Phase 3	25	Other|Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0709-24|R076477-AUT-4002	November 2007	September 2010	September 2010	October 26, 2007	May 16, 2017	May 16, 2017	Riley Child & Adolescent Psychiatry Clinic- Riley Hospital, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00549562
58	NCT00577447	Docosahexaenoic Acid in the Treatment of Autism		Completed	No Results Available	Autism	Dietary Supplement: docosahexaenoic acid (DHA)|Dietary Supplement: Placebo	Clinical Global Impressions-Improvement Scale|Child Development Inventory|Behavior Assessment Scale for Children|Aberrant Behavior Checklist	Mayo Clinic|DSM Nutritional Products, Inc.	All	3 Years to 10 Years   (Child)	Not Applicable	48	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	398-05	October 2005	September 2007	November 2007	December 20, 2007		April 28, 2015	Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT00577447
59	NCT00787111	Extended Management and Measurement of Autism	EMMA	Terminated	No Results Available	Autistic Disorder	Drug: Fluoxetine (prozac)	Safety Outcomes: Laboratory determinations, Urine drugs of abuse tests,Vital Signs,Physical Examinations, Adverse Events/Serious Adverse Events, Clinical Global Impression of Severity (CGI-S AD)	Neuropharm|Autism Speaks	All	5 Years to 18 Years   (Child, Adult)	Phase 3	128	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NPL-2008-4-AUTUS-005	November 2008	April 2009	April 2009	November 7, 2008		February 23, 2010	Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois, Chicago, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Harvard Medical School, Medford, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|CRCNJ, Voorhees, New Jersey, United States|Long Island Jewish Hospital, Bethpage, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Seattle Children's Hosptial University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00787111
60	NCT03487770	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder		Completed	No Results Available	Autistic Disorder	Drug: Aripiprazole Oral Solution|Drug: Placebo Oral Solution	Changes from Baseline to Week 8 (or endpoint) in the ABC-I score|Clinician-rated CGI-I score at Week 8 (or endpoint)|Change in ABC subscale scores from Baseline to Week 8 (or endpoint)|Response Rate at Week 8 (or endpoint) (or endpoint)	Otsuka Beijing Research Institute	All	6 Years to 17 Years   (Child)	Phase 3	111	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	031-403-00106	April 9, 2018	April 21, 2020	April 21, 2020	April 4, 2018		December 29, 2020	6th affiliated hospital, Peking University, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03487770
61	NCT02222285	An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)		Completed	No Results Available	Autistic Disorder	Other: Medical Food : Vayarin_005|Other: Placebo	Aberrant Behavior Checklist will be used to asses Autism spectrum symptoms|Clinical Global Impression of Severity assesment|Clinical Global Impression of Improvement assesment|Conners Rating Scale questionnaire|Behavior Rating Inventory of Executive function|Child Health Questionnaire|Caregiver Strain Questionnaire|Adverse events monitoring	Enzymotec	All	6 Years to 17 Years   (Child)	Not Applicable	56	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	Vayarin_005	August 2014	May 2017	October 2017	August 21, 2014		April 11, 2018	Institute of Neurology and Neurosurgery at St. Barnabas, Livingston, New Jersey, United States|Spectrum Neuroscience and Treatment Institute, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02222285
62	NCT01230359	Early Nutritional Intervention in Patients With Autism Spectrum Disorders		Completed	No Results Available	Autism Spectrum Disorders|Stable Clinical Condition in the Last 3 Months	Dietary Supplement: Pyridoxine hydrochloride|Other: Tang orange powder	Measurement of improvement in blood parameters|Developmental assessments for ASD	Hamad Medical Corporation|Qatar University|Heidelberg University	All	2 Years to 10 Years   (Child)	Not Applicable	40	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	8225/08	April 2010	July 2011	July 2011	October 29, 2010		July 19, 2011	Rumailah Hospital, Doha, Qatar		https://ClinicalTrials.gov/show/NCT01230359
63	NCT04326231	Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study		Recruiting	No Results Available	Autism Spectrum Disorder	Device: Usability assessment of Cognoa ASD Therapeutic Device	Usability assessment of Cognoa ASD Therapeutic Device	Cognoa, Inc.	All	3 Years to 8 Years   (Child)	Not Applicable	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	PRO-003	March 17, 2020	July 31, 2020	July 31, 2020	March 30, 2020		March 31, 2020	Cognoa, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT04326231
64	NCT05444816	Brain Hero® Neurofeedback Training (With the Device Brainhero 2019, Type 201)		Enrolling by invitation	No Results Available	Autism Spectrum Disorder	Device: Personalised Neurofeedback training at home	change in Z-score of the trained EEG parameter(s) (power in any frequency bin 1-30 Hz). (Z before minus Z after the training) divided by the number of trained parameters; Z is the number of standard deviations away from the neurotypical average|change in absolute power value (squared microvolts) of the trained EEG parameter(s) (power in any frequency bin 1-30 Hz).|change in scores of the Social Responsiveness Scale 2 (and/or subscales)|change in scores of the Behavioral Rating Inventory of Executive Function (and/or subscales)	Brainhero GmbH	All	6 Years to 18 Years   (Child, Adult)	Not Applicable	21	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MyMind_CIP_001	April 14, 2021	December 31, 2022	December 31, 2022	July 6, 2022		July 6, 2022	Praxis Jordangasse, Jordangasse 7A, Top 1/2, Vienna, Austria|Brainhero GmbH, Vienna, Austria		https://ClinicalTrials.gov/show/NCT05444816
65	NCT04016701	VR for Joint Attention Support in ASD		Withdrawn	No Results Available	Autism Spectrum Disorder	Device: Floreo Joint Attention Module|Behavioral: Regularly Scheduled Therapy	Change from Baseline Joint Attention Protocol score at 12 weeks|Change from Baseline Joint Attention Assessment score at 12 weeks|Change from Baseline Vineland Adaptive Behavior Scales, Third Edition total score	Floreo, Inc.	All	7 Years to 17 Years   (Child)	Phase 2	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Floreo Salus Protocol 1	July 20, 2018	July 16, 2019	July 16, 2019	July 11, 2019		July 17, 2019	Children's SPOT, Columbia, Maryland, United States		https://ClinicalTrials.gov/show/NCT04016701
66	NCT04233502	Efficacy and Safety of Slenyto for Insomnia in Children With ASD	ASD	Withdrawn	No Results Available	Autism Spectrum Disorder	Drug: Melatonin|Drug: Placebo	Total Sleep Time (TST)|Sleep Latency (SL)|Longest Sleep Episode (LSE)	Neurim Pharmaceuticals Ltd.	All	2 Years to 18 Years   (Child, Adult)	Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	NEU_CH_7913	September 2020	September 2022	December 2022	January 18, 2020		March 12, 2021			https://ClinicalTrials.gov/show/NCT04233502
67	NCT04944901	28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder		Completed	No Results Available	Autistic Disorder	Drug: SB-121|Drug: Placebo	Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESIs), and adverse events (AEs) leading to discontinuation from the study|Incidence of presence of L. reuteri and Sephadex® microspheres in the stool|Incidence of symptomatic bacteremia with positive L. reuteri identification|Change from baseline in Clinical Global Impressions Severity (CGI-S) Subscales|Change from baseline in Clinical Global Impressions Improvement (CGI-I) Subscales|Change from baseline in Vineland Adaptive Behavior Scales (3rd edition)|Change from baseline in Aberrant Behavior Checklist (ABC)|Change from baseline in Woodcock Johnson 3rd Edition (WJ-III)|Change from baseline in Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Change from baseline in Test of Attentional Performance for Children (KiTap)|Change from baseline in Neurophysiology Measures: electroencephalogram (EEG) resting state|Change from baseline in Neurophysiology Measures: auditory habituation|Change from baseline in Neurophysiology Measures: chirp modulated sweep auditory evoked response|Change from baseline in eye tracking|Change from baseline in Biomarkers: plasma oxytocin|Change from baseline in Biomarkers: plasma vasopressin|Change from baseline in Biomarkers: serum high-sensitivity C-reactive protein (hs-CRP)|Change from baseline in Biomarkers: tumor necrosis factor-α|Change from baseline in Biomarkers: stool biomarkers	Scioto Biosciences, Inc.	All	15 Years to 45 Years   (Child, Adult)	Phase 1	15	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SBI-SB121-20-01	August 2, 2021	March 3, 2022	March 3, 2022	June 30, 2021		April 1, 2022	Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT04944901
68	NCT05371912	Enhancement of Behavioral and Cognitive Outcomes in Autism Spectrum Disorder Via Neurostimulation		Recruiting	No Results Available	Autism Spectrum Disorder	Device: Trans Cranial Magnetic Stimulation	The effects of rTMS on reciprocal social cognition|The effects of rTMS on reciprocal rigid patterns of behavior|The effect of rTMS on verbal fluency|The effects of rTMS on executive function	Christiana Care Health Services|Dupont Applied Biosciences	All	5 Years to 25 Years   (Child, Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	DDD 604994	March 15, 2022	October 31, 2023	April 30, 2024	May 12, 2022		May 12, 2022	Mitra Assadi, Newark, Delaware, United States		https://ClinicalTrials.gov/show/NCT05371912
69	NCT02617342	Robot-Mediated Intervention for Children With Autism Spectrum Disorders		Active, not recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Robot-mediated Intervention	Change in baseline emotions accurately identified on the Transporters Quiz|Change in baseline Social Responsiveness Scale Score|Number of prompt-free intervals during the treatment sessions|Change in baseline parent report of child's emotion recognition	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Aetna, Inc.	All	4 Years to 8 Years   (Child)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00067744	November 2015	March 2023	March 2023	November 30, 2015		April 1, 2022	Kennedy Krieger Institute, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02617342
70	NCT01366859	Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior		Completed	No Results Available	Autism Spectrum Disorders	Dietary Supplement: Whey Protein|Dietary Supplement: Rice Protein (Placebo)	Behavioral Analysis|Safety Analysis|Intracellular Glutathione & Antioxidant Capacity	Nova Southeastern University|Immunotec Inc.	All	3 Years to 5 Years   (Child)	Phase 2	81	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)	01291001F	May 2011	October 2016	October 2016	June 6, 2011		November 3, 2016	Nova Southeastern University Clinic, Fort Lauderdale, Florida, United States|Nova Southeastern University, College of Pharmacy, Fort Lauderdale, Florida, United States|Mailman Segal Center, Ft. Lauderdale, Florida, United States		https://ClinicalTrials.gov/show/NCT01366859
71	NCT03379662	An Evaluation of Low Level Laser Light Therapy for Autistic Disorder		Completed	Has Results	Autistic Disorder	Device: Erchonia HLS Laser|Device: Placebo Laser	Mean Change From Baseline to Study Endpoint in the Aberrant Behavior Checklist (ABC) Irritability & Agitation Subscale Score.	Erchonia Corporation	All	5 Years to 17 Years   (Child)	Not Applicable	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EC_AUT_001	July 2, 2017	October 28, 2017	November 28, 2017	December 20, 2017	May 27, 2021	May 27, 2021	Institute for Brain and Rehabilitation Sciences, Nazareth, Israel	"Study Protocol, Statistical Analysis Plan, and Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03379662/Prot_SAP_ICF_000.pdf	https://ClinicalTrials.gov/show/NCT03379662
72	NCT02757066	Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders	NPC-15-5	Completed	No Results Available	Sleep Disorders|Autism Spectrum Disorder	Drug: NPC-15 Granules Lower Dose|Drug: NPC-15 Granules Higher Dose|Drug: NPC-15 Placebo Granule	Sleep latency with electronic sleep diary|Sleep latency measured by actigraphy|Abnormal behavior checklist Japanese version|Adverse events|Electro cardiogram	Nobelpharma	All	6 Years to 15 Years   (Child)	Phase 2|Phase 3	196	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NPC-15-5	June 16, 2016	September 2018	September 14, 2018	April 29, 2016		April 16, 2019			https://ClinicalTrials.gov/show/NCT02757066
73	NCT01474278	A Study of RO5028442 in Adult Male High-Functioning Autistic Patients		Completed	No Results Available	Autistic Disorder	Drug: Placebo|Drug: RO5028442	Efficacy: Behavior assessments|Safety: Incidence of adverse events	Hoffmann-La Roche	Male	18 Years to 45 Years   (Adult)	Phase 1	19	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)	BP27801	December 2011	March 2013	March 2013	November 18, 2011		November 2, 2016	Los Ageles, California, United States|New Haven, Connecticut, United States|Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT01474278
74	NCT02255565	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study		Completed	Has Results	ADHD|Autism	Drug: Very Low Dose Quillivant XR|Drug: Low Dose Quillivant XR|Drug: Moderate Dose Quillivant XR	ADHD Rating Scale - IV|Clinical Global Impressions-ADHD - Severity|Clinical Global Impression - Improvement (CGI-I)	Seattle Children's Hospital|Pfizer	All	5 Years to 16 Years   (Child)	Phase 4	36	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	WI185890	September 2014	September 2016	October 2016	October 2, 2014	June 5, 2017	August 1, 2017	Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02255565
75	NCT02069977	Study to Evaluate the Efficacy and Safety of Aripiprazole		Unknown status	No Results Available	Autism	Drug: Aripiprazole	irritability subscale of the aberrant behavior checklist|Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech|Change of CGI-S, CGI-I from baseline|Change of Behavioral problems from baseline|Change of Adaptive Skills from baseline|Change of Parental stress from baseline	Yoo-Sook Joung|Korea Otsuka International Asia Arab|Samsung Medical Center	All	6 Years to 17 Years   (Child)	Phase 4	79	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	031OTC1301	February 2014	February 2016	February 2016	February 24, 2014		March 11, 2014	Inje University Ilsan Paik Hospital, Ilsan, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Medical City, Pasig, Philippines|Philippine Children's Medical Center, Quezon City, Philippines|Siriraj Hospital Mahidol University, Bangkok, Thailand		https://ClinicalTrials.gov/show/NCT02069977
76	NCT01617460	A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder		Completed	Has Results	Autistic Disorder	Drug: Aripiprazole	Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score	Otsuka Pharmaceutical Co., Ltd.	All	6 Years to 17 Years   (Child)	Phase 3	86	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	031-11-003	September 2012	October 2016	October 2016	June 12, 2012	October 20, 2017	October 20, 2017	Chubu Region, Japan|Chugoku Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan		https://ClinicalTrials.gov/show/NCT01617460
77	NCT01617447	A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder		Completed	Has Results	Autistic Disorder	Drug: Placebo of Aripiprazole|Drug: Aripiprazole	Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score	Otsuka Pharmaceutical Co., Ltd.	All	6 Years to 17 Years   (Child)	Phase 3	92	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	031-11-002	July 2012	June 2015	June 2015	June 12, 2012	April 11, 2017	April 11, 2017	Chubu Region, Japan|Chugoku Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan		https://ClinicalTrials.gov/show/NCT01617447
78	NCT03715153	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.		Terminated	No Results Available	Autism Spectrum Disorder (ASD)	Drug: BUMETANIDE/S95008|Drug: PLACEBO	Childhood Autism Rating Scale, Second Edition (CARS2) total raw score|Social Responsiveness Scale, Second Edition (SRS-2) total raw score|Clinical Global Impression - Global Improvement (CGI-I) score|Vineland Adaptative Behaviour Scale II (VABS II)|Adverse Event and Pediatric Adverse Event Rating Scale (PAERS)|Abnormalities in 12-leads electrocardiogram (ECG) parameters|Renal ultrasound|Columbia-Suicide severity scale Children's version (C-SSRS-C)|Acceptability and palatability questionnaires|Paediatric Quality of Life Inventory (PedsQL) questionnaire	Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier	All	2 Years to 6 Years   (Child)	Phase 3	211	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CL3-95008-002|2017-004420-30	October 4, 2018	October 26, 2021	October 26, 2021	October 23, 2018		January 11, 2022	Richmond Behavioral Associates, Staten Island, New York, United States|Liverpool Hospital, Liverpool, Australia|The Royal Children's Hospital Melbourne, Parkville, Australia|Trial Tech em Pesquisas com Medicamentos Ltda, Curitiba, Brazil|Hospital Universitário Walter Cantídio-Universidade Federal do Ceará, Fortaleza, Brazil|Clínica Neurológica e Neurocirúrgica de Joinville, Joinville, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil|Faculdade de Medicina da Universidade de São Paulo - Departamento de psiquiatra, São Paulo, Brazil|University hospital of Ostrava, Department of Psychiatry, Poruba, Ostrava, Czechia|University Hospital Brno, Department of Child Neurology, Brno, Czechia|Institute of Neuropsychiatric Care, Department of Child Psychiatry, Praha, Czechia|GSC CHU-LENVAL Centre ressource autisme, Nice, Alpes-Maritimes, France|Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France|Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France|Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211, Bron Cedex, Auvergne-Rhône-Alpes, France|Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent, Paris, Ile De France, France|CHU Rouen, Rouen, Normandie, France|Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme, Sotteville-lès-Rouen, Normandie, France|Hôpital des Enfants-Pellegrin, Bordeaux, Nouvelle Aquitaine, France|Centre Hospitalier Charles Perrens CRA Aquitaine, Bordeaux, Nouvelle-Aquitaine, France|Vadaskert Korhaz es Szakambulancia, Budapest, Hungary|Servus Salvus Kft., Budapest, Hungary|Magyar Református Egyház Bethesda Gyermekkórháza, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary|Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o, Szeged, Hungary|Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini, Bosisio Parini, Lombardia, Italy|U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Lombardia, Italy|Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy|Programma Interdipartimentale "Autismo 0-90" A.O.U. Policlinico "Gaetano Martino", Messina, Sicilia, Italy|U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris, Calambrone, Toscana, Italy|U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy|"Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Poland|Centrum Badań Klinicznych PI-House sp. z o.o, Gdansk, Poland|NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi, Lodz, Poland|Fundacja SYNAPSIS ul., Warszawa, Poland|Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego, Warszawa, Poland|Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico, Coimbra, Portugal|National Institute of Children Diseases, Department of Child Psychiatry, Bratislava, Slovakia|EPAMED, s.r.o., Košice, Slovakia|Hospita Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Niño Jesus, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Colchester Hospital, Colchester, United Kingdom|ReCognition Health, London, United Kingdom|The Winnicott Centre 195-197 Hathersage Road, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT03715153
79	NCT01227668	Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder		Completed	Has Results	Irritability Associated With Autistic Disorder	Drug: Aripiprazole|Drug: Placebo	Percentage of Patients Relapsing by Week 16|Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])|Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])|Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1	Bristol-Myers Squibb	All	6 Years to 17 Years   (Child)	Phase 4	215	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CN138-603	March 2011	June 2012	June 2012	October 25, 2010	May 2, 2014	May 2, 2014	Harmonex Neuroscience Research, Inc, Dothan, Alabama, United States|Southwest Autism Research And Resource Center, Phoenix, Arizona, United States|Clinical Innovations, Inc., Costa Mesa, California, United States|Behavioral Research Specialists, Llc, Glendale, California, United States|Abbey Neuropsychology Clinic, Palo Alto, California, United States|Ucsf - Lppi, San Francisco, California, United States|Stanford University School Of Medicine, Stanford, California, United States|Children'S National Medical Center, Washington, District of Columbia, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|Florida Clinical Research Center, Llc, Maitland, Florida, United States|Miami Children'S Hospital, Miami, Florida, United States|University Of South Florida, Tampa, Florida, United States|Institute For Behavioral Medicine, Llc, Smyrna, Georgia, United States|Kootenai Behavioral Health Center, Coeur D'Alene, Idaho, United States|Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States|Lsu Health Sciences Center, Shreveport, Louisiana, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Center For Psychiatry And Behavioral Medicine, Inc, Las Vegas, Nevada, United States|Clinical Research Center Of New Jersey, Gibbsboro, New Jersey, United States|Children'S Specialized Hosp, Toms River, New Jersey, United States|Stony Brook University School Of Medicine, Stony Brook, New York, United States|Unc Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Ou Physician'S Child Study Center, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute And Clinic, Pittsburgh, Pennsylvania, United States|Holston Medical Group, Kingsport, Tennessee, United States|Insite Clinical Research, Desoto, Texas, United States|Ericksen Research And Development, Clinton, Utah, United States|Childrens Specialty Gr., Pllc, Norfolk, Virginia, United States|Virginia Treatment Center For Children, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT01227668
80	NCT00850070	Sapropterin as a Treatment for Autistic Disorder		Completed	Has Results	Autistic Disorder	Drug: sapropterin|Drug: Placebo	Clinical Global Impression -- Improvement (CGI-I) Scale|Clinical Global Impression -- Severity (CGI-S) Scale|Preschool Language Scale-Fourth Edition (PLS-4). Assesses Expressive and Receptive Language Skills in Ages Birth Through 6 Years, 11 Months.|Vineland Adaptive Behavior Scale-II.|Children's Yale Brown Obsessive Compulsive Scale (C-YBOCS)|Connor's Preschool ADHD Questionnaire|Adverse Events Scale|Aberrant Behavior Checklist (ABC) - Inappropriate Speech|Social Responsiveness Scale (SRS)|Parent Global Assessment (PGA) Scale	The Children's Health Council|BioMarin Pharmaceutical	All	3 Years to 6 Years   (Child)	Phase 2	46	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CHC-0901	March 2009	August 2011	October 2011	February 24, 2009	February 28, 2014	May 1, 2018	The Children's Health Council, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT00850070
81	NCT01116388	A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders	GFCF	Completed	No Results Available	Autism|Gastrointestinal Symptoms	Other: GFCF product with GFCF diet|Other: product containing gluten and casein (milk protein) with GFCF diet	A study to assess the role of a gluten free-casein free diet in the dietary management of autism associated gastrointestinal disorders	Massachusetts General Hospital|Nutricia North America	All	2 Years to 17 Years   (Child)	Not Applicable	65	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2008-P-002385	April 2010	April 2015	April 2015	May 5, 2010		April 8, 2015	Massachusetts General Hospital, Boston, Massachusetts, United States|Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01116388
82	NCT00943579	Open-Label Extension Study of Kuvan for Autism		Completed	Has Results	Autistic Disorder	Drug: Kuvan®	Clinical Global Impressions Scale|Vineland Adaptive Behavior Scale, 2nd Edition|Children's Yale Brown Obsessive Compulsive Scale|Parental Global Assessment|Preschool Language Scale, 4th Edition (PLS-4)|Connor's Preschool ADHD Questionnaire|Aberrant Behavior Checklist (ABC)|Adverse Events Reporting	The Children's Health Council|BioMarin Pharmaceutical	All	3 Years to 6 Years   (Child)	Phase 2|Phase 3	41	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHC-0902	August 2009	December 2011	March 2012	July 22, 2009	July 4, 2013	May 2, 2018	The Children's Health Council, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT00943579
83	NCT01624675	A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder		Completed	No Results Available	Autistic Disorder in Children and Adolescents	Drug: Risperidone|Drug: Placebo	The change from baseline in the Aberrant Behavior Checklist-Japanese Version (ABC-J) Irritability Subscale scores|The changes from baseline in the subscale scores of Aberrant Behavior Checklist-Japanese Version (ABC-J) at each evaluation of the double-blind phase|The changes from baseline in the subscale scores of Aberrant Behavior Checklist-Japanese Version (ABC-J) at each evaluation of the open-label phase|The changes from baseline in scores of the Clinical Global Impression - Severity (CGI-S) at each evaluation time point of the double-blind phase|The changes from baseline in scores of the Clinical Global Impression - Severity (CGI-S) at each evaluation time point of the open-label-phase|The changes from baseline in scores of the Children's Global Assessment Scale (C-GAS) at each evaluation time point of the double-blind phase and open-label-phase|The changes from baseline in scores of the Children's Global Assessment Scale (C-GAS) at each evaluation time point of open-label-phase|The Clinical Global Impression-Change (CGI-C) at each evaluation time point of the double-blind phase|The Clinical Global Impression-Change (CGI-C) at each evaluation time point of the open label-phase|The Parent Satisfaction Questionnaire (PSQ) at each evaluation time point of the double-blind phase|The Parent Satisfaction Questionnaire (PSQ) at each evaluation time point of the open label-phase	Janssen Pharmaceutical K.K.	All	5 Years to 17 Years   (Child)	Phase 3	39	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CR100877|RIS-AUT-JPN-01	September 2012	October 2014	October 2014	June 21, 2012		October 15, 2015	Fuchu, Japan|Fukui, Japan|Hirakata, Japan|Ichikawa, Japan|Kanzaki, Japan|Kobe, Japan|Kodaira, Japan|Kurashiki, Japan|Neyagawa, Japan|Okayama, Japan|Sakai, Japan|Shimotsuke, Japan|Tokyo, Japan|Toyama, Japan|Tsuyama, Japan|Tsu, Japan|Yokohama, Japan		https://ClinicalTrials.gov/show/NCT01624675
84	NCT04578756	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder		Recruiting	No Results Available	Schizophrenia|Bipolar I Disorder|Autism Spectrum Disorder (ASD)	Drug: Cariprazine Flexible Dose	Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period|Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters|Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters|Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)|Number of Participants With Suicidal Ideation or Suicidal Behavior as Recorded on the Columbia-Suicide Severity Rating (C-SSRS) Scale|Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)|Change From Baseline in Barnes Akathisia Rating Scale (BARS)|Change From Baseline in Simpson-Angus Scale (SAS)|Number of Participants With Clinically Significant Changes From Baseline in Opthalmologic Parameters|Number of Participants With Menstrual Onset Shift (Female Participants Only)|Incidence of Participants Shifting in Tanner Staging	AbbVie	All	10 Years to 17 Years   (Child)	Phase 3	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3070-301-001	February 1, 2021	June 4, 2023	May 29, 2024	October 8, 2020		August 26, 2022	Harmonex Neuroscience Research /ID# 234938, Dothan, Alabama, United States|Pillar Clinical Research /ID# 236434, Bentonville, Arkansas, United States|Advanced Research Center /ID# 241903, Anaheim, California, United States|Alliance for Research - Long Beach /ID# 236261, Long Beach, California, United States|Prospective Research Innovations Inc /ID# 236098, Rancho Cucamonga, California, United States|University of California, San Diego Department of Psychiatry /ID# 236466, San Diego, California, United States|Pacific Clinical Research Management Group /ID# 234377, Upland, California, United States|Sarkis Clinical Trials /ID# 236893, Gainesville, Florida, United States|Galiz Research - Palmetto Medical Plaza /ID# 236277, Hialeah, Florida, United States|Advanced Research Institute of Miami /ID# 242505, Homestead, Florida, United States|South Florida Research Ph I-IV /ID# 237453, Miami Springs, Florida, United States|Columbus Clinical Services, Llc /Id# 234281, Miami, Florida, United States|Florida Research Center, Inc. /ID# 236515, Miami, Florida, United States|Links Clinical Trials /ID# 240975, Miami, Florida, United States|Atlanta Center for Medical Research /ID# 234698, Atlanta, Georgia, United States|iResearch Atlanta, LLC /ID# 237391, Decatur, Georgia, United States|Atlanta Behavioral Research, LLC /ID# 236374, Dunwoody, Georgia, United States|Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 242611, Stockbridge, Georgia, United States|AMITA Health St. Mary and St. Elizabeth Medical Ctr /ID# 235857, Chicago, Illinois, United States|The Kennedy Krieger Institute /ID# 236360, Baltimore, Maryland, United States|Med Clinical Research Partners LLC /ID# 236071, Irvington, New Jersey, United States|Erie County Medical Center /ID# 237204, Buffalo, New York, United States|University of Cincinnati /ID# 236913, Cincinnati, Ohio, United States|CincyScience /ID# 236390, West Chester, Ohio, United States|Cutting Edge Research Group /ID# 236664, Oklahoma City, Oklahoma, United States|BioBehavioral Research of Austin /ID# 236479, Austin, Texas, United States|Relaro Medical Trials /ID# 241960, Dallas, Texas, United States|McGovern Medical School /ID# 238506, Houston, Texas, United States|Red Oak Psychiatry Associates /ID# 236602, Houston, Texas, United States|AIM Trials /ID# 236368, Plano, Texas, United States|Family Psychiatry of The Woodlands /ID# 236426, The Woodlands, Texas, United States|Dr. Samuel Sanchez PSC /ID# 246047, Caguas, Puerto Rico|GCM Medical Group PSC /ID# 246048, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT04578756
85	NCT02199925	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum		Unknown status	No Results Available	Autism|Autistic Disorder|Asperger's Disorder|PDD|Pervasive Developmental Disorder	Drug: Gammaplex 5%	The primary objective is to assess the efficacy of Gammaplex as an immunomodulatory therapy in autistic children with evidence of immune dysfunction.|The modulatory effect of IVIG on neuroinflammation will be assessed by laboratory measurements which we believe are indicative of immune dysregulation.	Isaac Melamed|Bio Products Laboratory|IMMUNOe Research Centers	All	4 Years to 12 Years   (Child)	Phase 4	30	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GMXAUT01	June 2013	April 2015	July 2015	July 25, 2014		April 16, 2015	IMMUNOe International Research Centers, Centennial, Colorado, United States		https://ClinicalTrials.gov/show/NCT02199925
86	NCT05307744	Effects of Lactobacillus Plantarum PS128 in Children With ASD		Recruiting	No Results Available	Autism Spectrum Disorder	Dietary Supplement: PS128|Other: Placebo	Changes of total scores of Social Responsiveness Scale|Changes of total scores of Repetitive Behavior Scale-Revised|Changes of total scores of Child Behavior Checklist|Changes of total scores of Adaptive Behavior Assessment System|Changes in accuracy of Frith-Happe animation|Changes in accuracy of Eyes task|Changes of total scores of Aberrant Behavior Checklist|Visual Analogue Scale for GI symptoms|Changes of total scores of Emotional Dysregulation Inventory|Changes of total scores of Parenting Stress Index, Fourth Editon|Assessment of Clinical Global Impression-Severity of Illness|Assessment of Patient Global Impression of Change|Gut microbiota|MRI T1|functional MRI (resting-state/biological motion task) - BOLD signal|Diffusion Tensor Imaging (DTI) - FA|Safety assessment - Albumin|Safety assessment - Total Protein|Safety assessment - ALP|Safety assessment - Total Bilirubin|Safety assessment - T-Cholesterol|Safety assessment - Uric Acid|Safety assessment - BUN|Safety assessment - Creatinine|Safety assessment - AST|Safety assessment - ALT|Change in levels of exploratory blood-based biomarkers for inflammatory changes - MPO|Change in levels of exploratory blood-based biomarkers for inflammatory changes - IL-1β|Change in levels of exploratory blood-based biomarkers for inflammatory changes - TGF-β1|Change in levels of exploratory blood-based biomarkers for inflammatory changes - Eotaxin|Change in levels of exploratory blood-based biomarkers for inflammatory changes - IL-6|Change in levels of exploratory blood-based biomarkers for oxidative stress changes - Serotonin|Change in levels of exploratory blood-based biomarkers for oxidative stress changes - GABA|Change in levels of exploratory blood-based biomarkers for oxidative stress changes - Cortisol	Chang Gung Memorial Hospital|Bened Biomedical Co., Ltd.	All	7 Years to 12 Years   (Child)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	202101416A3	July 15, 2022	July 31, 2025	December 31, 2026	April 1, 2022		July 22, 2022	Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT05307744
87	NCT05015439	Cannabidiol (CBD) in Adults With ASD		Recruiting	No Results Available	Autism Spectrum Disorder	Drug: Cannabidiol|Drug: Placebo	Change in Aberrant Behaviors as assessed by the Aberrant Behavior Checklist|Change in Anxiety as assessed by the Hamilton Anxiety Rating Scale|Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Change in Clinical Global Impression Scale-Improvement (CGI)|Change in neuropsychiatric symptomatology as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)|Change in Waisman Activities of Daily Living scale|Change in Social Communication Questionnaire|Change in Mini Mental State Examination (MMSE)|Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Subjective|Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Informant|Change in Adverse Effects- Medication Side-Effects Questionnaire	Johns Hopkins University|Canopy Growth Corporation	All	18 Years and older   (Adult, Older Adult)	Phase 1	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00267739	December 2022	December 2023	March 2024	August 20, 2021		December 2, 2022	JHBMC, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT05015439
88	NCT03715166	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder		Terminated	No Results Available	Autism Spectrum Disorder (ASD)	Drug: Bumetanide Oral Solution|Drug: Placebo	Childhood Autism Rating Scale, Second Edition (CARS2) total raw score|Social Responsiveness Scale, Second Edition (SRS-2) total raw score|Clinical Global Impression - Global Improvement (CGI-I) score|Vineland Adaptative Behaviour Sales, Second Edition (VABS II) subscores|Adverse events and Paediatric Adverse Event Rating Scale (PAERS)|Abnormalities in 12-leads electrocardiogram (ECG) parameters|Renal ultrasound|the Columbia Suicide Severity Rating Scale Children's version (C-SSRS-C)|Tanner stage|Acceptability and palatability questionnaire|Paediatric Quality of Life Inventory (PedsQL) questionnaire	Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier	All	7 Years to 17 Years   (Child)	Phase 3	211	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CL3-95008-001|2017-004419-38	September 24, 2018	September 13, 2021	September 13, 2021	October 23, 2018		March 29, 2022	Trial Tech em Pesquisas com Medicamentos Ltda, Curitiba, Brazil|Hospital Universitário Walter Cantídio - Universidade Federal do Ceará, Fortaleza, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil|Faculdade de Medicina da Universidade de São Paulo - Departamento de Psiquiatria, São Paulo, Brazil|GSC CHU-LENVAL Centre ressource autisme, Nice, Alpes-Maritimes, France|Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France|Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France|Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211, Bron, Auvergne-Rhône-Alpes, France|Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent, Paris, Il De France, France|CHU Rouen, Rouen, Normandie, France|Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme, Sotteville-lès-Rouen, Normandie, France|Hôpital des Enfants-Pellegrin, Bordeaux, Nouvelle Aquitaine, France|Centre Hospitalier Charles Perrens CRA Aquitaine, Bordeaux, Nouvelle-Aquitaine, France|Universitätsklinikum Freiburg, Zentrum für Psychische Erkrankungen, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter, Freiburg, Baden-Württemberg, Germany|Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Mannheim, Baden-Württemberg, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und, Dresden, Saxony (Sachsen), Germany|Vadaskert Korhaz es Szakambulancia, Budapest, Hungary|Servus Salvus Kft., Budapest, Hungary|Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary|Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o, Szeged, Hungary|Unità Semplice di Psichiatria Infantile Policlinico Universitario di Napoli - Università Federico II, Napoli, Campania, Italy|Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini, Bosisio Parini, Lombardia, Italy|U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Lombardia, Italy|Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy|Programma Interdipartimentale "Autismo 0-90" A.O.U. Policlinico "Gaetano Martino", Messina, Sicilia, Italy|U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris, Calambrone, Toscana, Italy|U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy|Accare Groningen, Groningen, Netherlands|NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi, Lodz, Wojewodztwo Lodzkie, Poland|Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego, Warszawa, Wojewodztwo Mazowieckie, Poland|Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Wojewodztwo Pomorskie, Poland|Centrum Badań Klinicznych PI-House sp. z o.o, Gdansk, Poland|Fundacja SYNAPSIS ul., Warszawa, Poland|Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico, Coimbra, Portugal|Hospita Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Niño Jesus, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Forward Thinking Birmingham_Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom|ReCognition Health, London, United Kingdom|The Winnicott Centre, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT03715166
89	NCT00380692	Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder		Completed	Has Results	Autistic Disorder|Attention Deficit Disorder With Hyperactivity	Drug: Atomoxetine|Drug: Placebo	ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score|Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)|Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)|ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score|Sleep Measure Scale|Aberrant Behavior Checklist (ABC)|Children's Social Behavior Questionnaire (CSBQ) Total Score|General Health Questionnaire (GHQ) Total Score|Nijmeegse Ouderlijke Stress Index (NOSI) Total Score|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy|Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement|Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times|Cytochrome P450 2D6 Genotype	Eli Lilly and Company	All	6 Years to 17 Years   (Child)	Phase 4	97	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	10483|B4Z-UT-S017	October 2006	May 2008	October 2008	September 26, 2006	July 8, 2009	May 11, 2010	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoorn, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oosterhout, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT00380692
90	NCT03337646	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism		Recruiting	No Results Available	Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder	Drug: Lisdexamfetamine Dimesylate	ADHD Symptoms|Health Related Quality of Life|Executive Function|Severity of illness|Improvement of Subjects|Safety-Adverse events|Safety - suicidality	JPM van Stralen Medicine Professional|Shire	All	6 Years to 12 Years   (Child)	Phase 4	40	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RES 16-002	September 26, 2018	December 31, 2022	December 31, 2022	November 9, 2017		March 29, 2022	Center for Pediatric Excellence, Ottawa, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03337646
91	NCT04156646	A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers		Completed	Has Results	Autism Spectrum Disorder	Drug: Balovaptan|Drug: Esomeprazole	Maximum Plasma Concentration (Cmax) of Balovaptan|Mean Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Balovaptan|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of Balovaptan|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Balovaptan|Time to Reach Cmax in Plasma (Tmax) of Balovaptan|Last Quantifiable Concentration (Clast) of Balovaptan|Time To the Last Quantifiable Concentration (Tlast) of Balovaptan|Time Between Dosing and Time of First Balovaptan Plasma Concentration (Tlag)|Apparent Clearance (Cl/F) of Balovaptan|Apparent Volume of Distribution (Vd/F) of Balovaptan|Terminal Elimination Phase Half-Life (T1/2) of Balovaptan|Terminal Phase Rate Constant (λz) of Balovaptan|Plasma Concentrations of Balovaptan|Maximum Plasma Concentration (Cmax) of M2 Metabolite|Maximum Plasma Concentration (Cmax) of M3 Metabolite|Maximum Plasma Concentration (Cmax) of Esomeprazole|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M2 Metabolite|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M3 Metabolite|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Esomeprazole|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M2 Metabolite|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M3 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M2 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M3 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Esomeprazole|Time to Reach Cmax in Plasma (Tmax) of M2 Metabolite|Time to Reach Cmax in Plasma (Tmax) of M3 Metabolite|Time to Reach Cmax in Plasma (Tmax) of Esomeprazole|Last Quantifiable Concentration (Clast) of M2 Metabolite|Last Quantifiable Concentration (Clast) of M3 Metabolite|Last Quantifiable Concentration (Clast) of Esomeprazole|Time To the Last Quantifiable Concentration (Tlast) of M2 Metabolite|Time To the Last Quantifiable Concentration (Tlast) of M3 Metabolite|Time To the Last Quantifiable Concentration (Tlast) of Esomeprazole|Terminal Elimination Phase Half-Life (T1/2) of M2 Metabolite|Terminal Elimination Phase Half-Life (T1/2) of M3 Metabolite|Terminal Elimination Phase Half-Life (T1/2) of Esomeprazole|Percentage of Patricipants With Adverse Events (AEs)|Terminal Phase Rate Constant (λz) of M2 Metabolite|Terminal Phase Rate Constant (λz) of M3 Metabolite|Terminal Phase Rate Constant (λz) of Esomeprazole|Plasma Concentrations of M2 Analyte|Plasma Concentrations of M3 Analyte|Plasma Concentrations of Esomeprazole	Hoffmann-La Roche	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	16	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WP41047	November 19, 2019	December 24, 2019	January 6, 2020	November 7, 2019	March 16, 2021	March 16, 2021	PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT04156646/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04156646
92	NCT04151290	Cognoa ASD Diagnosis Aid Validation Study		Completed	Has Results	Autism Spectrum Disorder	Diagnostic Test: Cognoa ASD diagnostic device	Positive and Negative Predictive Value of ASD Dx in Relation to Clinician Diagnostic Evaluation|No Result Percentage|Device Sensitivity and Specificity	Cognoa, Inc.	All	18 Months to 72 Months   (Child)	Not Applicable	711	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Q170886	August 7, 2019	June 5, 2020	August 31, 2020	November 5, 2019	December 28, 2021	December 28, 2021	Melmed Center, Scottsdale, Arizona, United States|The Nicholls Group, Scottsdale, Arizona, United States|Orange County Child Neurology, Laguna Niguel, California, United States|Pediatric Neurology of Orange County, Laguna Niguel, California, United States|Private Practice, Laguna Niguel, California, United States|Private Practice, Los Angeles, California, United States|Private Practice, Palo Alto, California, United States|MediSync Clinical Research Hattiesburg Clinic, Petal, Mississippi, United States|PriMed Clinical Research, Dayton, Ohio, United States|ARC Clinical Research at Wilson Parke, Austin, Texas, United States|ARC Clinical Research William Cannon, Austin, Texas, United States|ARC Clinical Research Kelly Lane, Pflugerville, Texas, United States|Texas Child Neurology, Plano, Texas, United States|Private Practice, Seattle, Washington, United States|Seattle Children's Hospital, Seattle, Washington, United States|Multicare Health System - Mary Bridge Pediatrics, Tacoma, Washington, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/90/NCT04151290/Prot_004.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/90/NCT04151290/SAP_005.pdf	https://ClinicalTrials.gov/show/NCT04151290
93	NCT03912350	The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan		Withdrawn	No Results Available	Autism Spectrum Disorder	Drug: Balovaptan	Plasma concentration of balovaptan|Plasma concentration of M2 metabolite, as applicable|Plasma concentration of M3 metabolite|AUC during the dosing interval on Day 1 of balovaptan|AUC during the dosing interval on Day 1 of M2 metabolite|AUC during the dosing interval on Day 1 of M3 metabolite|AUC during the dosing interval at steady state on Day 14 of balovaptan|AUC during the dosing interval at steady state on Day 14 of M2 metabolite|AUC during the dosing interval at steady state on Day 14 of M3 metabolite|Maximum observed plasma concentration (Cmax) of balovaptan|Maximum observed plasma concentration (Cmax) of M2 metabolite|Maximum observed plasma concentration (Cmax) of M3 metabolite|Time of maximum observed plasma concentration (Tmax) of balovaptan|Time of maximum observed plasma concentration (Tmax) of M2 metabolite|Time of maximum observed plasma concentration (Tmax) of M3 metabolite|Metabolite:Parent ratio of area under the plasma (MRauc) of M2 metabolite|Metabolite:Parent ratio of area under the plasma (MRauc) of M3 metabolite|Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M2 metabolite|Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M3 metabolite|Apparent volume of distribution (V/F) of balovaptan|Apparent volume of distribution (V/F) of M2 metabolite|Apparent volume of distribution (V/F) of M3 metabolite|Terminal phase rate constant (λZ) of balovaptan, when possible|Terminal phase rate constant (λZ) of M2 metabolite, when possible|Terminal phase rate constant (λZ) of M3 metabolite, when possible|Apparent terminal elimination half-life (t½) of balovaptan, when possible|Apparent terminal elimination half-life (t½) of M2 metabolite, when possible|Apparent terminal elimination half-life (t½) of M3 metabolite, when possible|Apparent plasma clearance after oral administration (CLss/F) of balovaptan, when possible|Apparent plasma clearance after oral administration (CLss/F) of M2 metabolite, when possible|Apparent plasma clearance after oral administration (CLss/F) of M3 metabolite, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of balovaptan, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M2 metabolite, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M3 metabolite, when possible|Percentage of participants with adverse events	Hoffmann-La Roche	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WP41045	June 26, 2022	September 24, 2022	October 13, 2022	April 11, 2019		February 8, 2022			https://ClinicalTrials.gov/show/NCT03912350
94	NCT03507569	Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513		Completed	Has Results	Autism Spectrum Disorder	Drug: RO7017773|Other: [11C] Ro15-4513	Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773|Plasma Concentrations of RO7017773|Number of Participants With Adverse Events (AEs)	Hoffmann-La Roche	All	23 Years to 55 Years   (Adult)	Phase 1	6	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BP40257	April 24, 2018	June 22, 2018	June 22, 2018	April 25, 2018	September 30, 2019	September 30, 2019	Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03507569/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03507569
95	NCT05602116	ASC - Autism Study		Not yet recruiting	No Results Available	Autism Spectrum Disorder|Gastrointestinal Dysfunction|Leaky Gut Syndrome|Mesenchymal Stromal Cells|Inflammatory Bowel Diseases	Drug: Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)	Safety of C2C_ASC (Adverse Events)|Changes in autism spectrum disorder|Changes in gastrointestinal symptoms	Cell2Cure ApS	All	6 Years to 14 Years   (Child)	Phase 1	10	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASC II	February 1, 2023	February 1, 2026	February 1, 2026	November 1, 2022		November 4, 2022			https://ClinicalTrials.gov/show/NCT05602116
96	NCT00619190	Study of Aripiprazole to Treat Children and Adolescents With Autism	PAIRS	Completed	Has Results	Autistic Disorder|Asperger Syndrome|Autism Spectrum Disorder	Drug: aripiprazole	Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks|Clinical Global Impressions Scale - Severity Score (CGI-S)|Change From Baseline in the Aberrant Behavior Checklist -Lethargy/Social Withdrawal Subscale at 12 Weeks	University of North Carolina, Chapel Hill|Bristol-Myers Squibb	All	30 Months to 17 Years   (Child)	Phase 2	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	04-1792 GCRC-2491	January 2006	June 2012	June 2012	February 20, 2008	March 26, 2014	March 26, 2014	University of North Carolina, Department of Psychiatry, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00619190
97	NCT02500771	Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1		Unknown status	No Results Available	Autism Spectrum Disorder	Behavioral: ABA therapy enhanced with V-Motive software	Feasibility of V-Motive software's ability to positively impact a child's performance within 4 weeks|Amount of time required to construct a fully-indexed video repository from therapy footage using V-Motive|Accuracy of V-Motive software in suggesting and cueing up appropriate video for playback on demand	Experiad LLC|northwest behavioral associates	All	4 Years and older   (Child, Adult, Older Adult)	Not Applicable	12	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VMOTIVE-1	June 2017	December 2020	December 2020	July 17, 2015		July 17, 2015	Northwest Behavioral Associates, Bellevue, Washington, United States		https://ClinicalTrials.gov/show/NCT02500771
98	NCT03829878	Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)	SPROUT	Withdrawn	No Results Available	Autism Spectrum Disorder|Autism|ASD|Autistic Thinking|Autistic Behavior|Finch|FMT|Fecal Microbiota Transplant|CP101|SPROUT|Fecal Transplant	Drug: CP101|Drug: Placebo	Childhoood Autism Rating Scales-2 (CARS-2)|Aberrant Behavior Checklist-2 (ABC-2)|Social Responsiveness Scale-2 (SRS-2)|Parent Global Impressions-III (PGI-III)|Gastrointestinal Symptom Rating Scale (GSRS)|Gastrointestinal Stool & Symptom Questionnaire for Autism (GSSQA)|Reynolds Intellectual Assessment Scales-2-Nonverbal (RIAS-2-NV)|Autism Diagnostic Interview-Revised (ADI-R)	Finch Research and Development LLC.	All	5 Years to 17 Years   (Child)	Phase 2	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CP101-ASD-203	May 2020	May 2020	December 2021	February 4, 2019		April 8, 2021			https://ClinicalTrials.gov/show/NCT03829878
99	NCT01337700	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism		Completed	Has Results	Autism Spectrum Disorder|Asperger Syndrome|Aspergers Syndrome	Drug: Milnacipran|Drug: Placebo	Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale|Change in Hyperactivity as Measured by Aberrant Behavior Checklist - Hyperactivity Scale|Change in Autism Severity Levels Based on the Clinical Global Impressions Scale|Change in Repetitive Behaviors Using YBOCS-Compulsion and Rigidity Subscale|Change in Diagnostic Analysis of Nonverbal Activity-2 ADULT FACIAL EXPRESSIONS: (DANVA2-AF)	Montefiore Medical Center|Forest Laboratories	All	18 Years to 50 Years   (Adult)	Phase 4	10	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	10-09-299	February 2011	July 2014	July 2014	April 19, 2011	February 27, 2020	February 27, 2020	Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT01337700
100	NCT01078844	Memantine in Adult Autism Spectrum Disorder		Terminated	Has Results	Autism|Asperger's Disorder|Pervasive Developmental Disorder NOS	Drug: memantine|Drug: Placebo	Clinical Global Impression-Scale(CGI-S)	Johns Hopkins University|Forest Laboratories	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	4	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NA_00015760	February 2010	July 2010	July 2010	March 2, 2010	July 26, 2017	July 26, 2017	Johns Hopkins Bayview, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01078844
101	NCT00308074	An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders		Completed	Has Results	Autism|Asperger's Disorder|Pervasive Developmental Disorder	Drug: Aripiprazole	Clinical Global Impressions-Improvement|Aberrant Behavior Checklist-Irritability Subscale|Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Brief Psychiatric Rating Scale for Children (BPRS-C)	Cambridge Health Alliance|Bristol-Myers Squibb	All	6 Years to 17 Years   (Child)	Phase 2	14	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHA-IRB-0119/06/05	February 2006	December 2008	February 2009	March 29, 2006	January 2, 2017	February 15, 2017	Cambridge Health Alliance, Medford, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00308074
102	NCT05361707	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances		Recruiting	No Results Available	Autism Spectrum Disorder|Sleep Disorder|Neurological Disorder|Sleep Disturbance	Drug: Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension	Change in sleep time over the treatment period, as measured by sleep diary.|Improvement in objective sleep-wake parameters such as severity of condition, as measured by administered questionnaires.|Improvement in objective behavioral parameters such as the participant's overall behavior, as measured by sleep diary in the Patient Global Impression of Severity Behavior Questionnaire (PGI-S Behavior).|Assessment of safety and tolerability of daily single dose of tasimelteon, as measured by spontaneous reporting of adverse events (AEs).	Vanda Pharmaceuticals	All	2 Years to 65 Years   (Child, Adult, Older Adult)	Phase 3	100	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VP-VEC-162-3601	July 28, 2021	July 2022	July 2023	May 5, 2022		May 5, 2022	Vanda Investigational Site, San Jose, California, United States|Vanda Investigational Site, San Leandro, California, United States|Vanda Investigational Site, Santa Monica, California, United States|Vanda Investigational Site, Boulder, Colorado, United States|Vanda Investigational Site, Staten Island, New York, United States		https://ClinicalTrials.gov/show/NCT05361707
103	NCT03724136	Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study	ACIST	Enrolling by invitation	No Results Available	Alzheimer Disease|Alzheimer Dementia|Vascular Dementia|Lewy Body Disease|Lewy Body Dementia With Behavioral Disturbance (Disorder)|Dementia, Mixed|Parkinson-Dementia Syndrome|Chronic Traumatic Encephalopathy|Huntington's Dementia|Wernicke Korsakoff Syndrome|Traumatic Brain Injury|Dementia, Multi-Infarct|Autism|Autism Spectrum Disorder|Autistic Behavior|Autistic Disorder, Current or Active State|Cadasil|LATE Limbic-predominant Age-related TDP-43 Encephalopathy	Procedure: Intravenous Bone Marrow Stem Cell (BMSC) Fraction|Procedure: Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Procedure: Near Infrared Light	Mini-Mental Status Exam (MMSE)|Autism Spectrum Quotient Exam|Activities of Daily Living	MD Stem Cells	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDSC-ACIST	October 24, 2018	October 2023	October 2024	October 30, 2018		August 2, 2022	MD Stem Cells, Westport, Connecticut, United States|MD Stem Cells, Coral Springs, Florida, United States|Medcare Orthopaedics & Spine Hospital, Dubai, United Arab Emirates		https://ClinicalTrials.gov/show/NCT03724136
104	NCT00110708	Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism		Unknown status	No Results Available	Autism|Autistic Disorder|Child Development Disorders, Pervasive|Gastrointestinal Diseases|Signs and Symptoms, Digestive	Drug: Oralgam (human immunoglobulin)	Global improvement in gastrointestinal function|Assessment of behavior (improvement and severity); additional assessments of gastrointestinal conditions	PediaMed Pharmaceuticals	All	2 Years to 18 Years   (Child, Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	Protocol 004	April 2005		June 2006	May 13, 2005		February 22, 2006	Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|Center for Autism Research and Education, Phoenix, Arizona, United States|University of California Davis, MIND Institute, Sacramento, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|University of Florida HSC, Gainesville, Florida, United States|International Child Development Resource Center, Melbourne, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Kansas Medical Center, Developmental Disabilities Center, Kansas City, Kansas, United States|Bluegrass Clinical Research, Louisville, Kentucky, United States|Gulf Coast Research, LLC, Baton Rouge, Louisiana, United States|Hardy Health Associates, Hingham, Massachusetts, United States|Pivotal Research Centers - Detroit, Royal Oak, Michigan, United States|Mercy Health Research, St. Louis, Missouri, United States|Robert Wood Johnson Medical School, Piscataway, New Jersey, United States|Strong Center for Developmental Disabilities, University of Rochester Medical Center, Rochester, New York, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Nisonger Center Ohio State University, Columbus, Ohio, United States|Merck Child Outpatient Clinic, Pittsburgh, Pennsylvania, United States|North San Antonio Healthcare Associates, San Antonio, Texas, United States|Autism Spectrum Treatment and Research Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00110708
105	NCT00584701	Pharmacogenomics in Autism Treatment	PG	Completed	Has Results	Autism	Drug: Risperidone	Percent Change of ABC - Irritability Subscale Score|Exon Expression Positively or Negatively Correlated With Percentage Improvement in ABC-I	University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)	All	4 Years to 18 Years   (Child, Adult)	Phase 2|Phase 3	49	Other|Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200715817-1|R21MH080026	January 2008	May 2009	May 2009	January 2, 2008	July 24, 2012	July 24, 2012	UC San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT00584701
106	NCT01592773	Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)		Terminated	Has Results	Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Drug: Memantine Hydrochloride (HCl)	Patients With Any Treatment-emergent Adverse Event	Forest Laboratories	All	6 Years to 12 Years   (Child)	Phase 2	747	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MEM-MD-69	October 2012	January 2014	March 2014	May 7, 2012	February 16, 2015	February 16, 2015	Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 066, Irvine, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 123, Fort Wayne, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 091, New Orleans, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 098, Bronx, New York, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 124, Roanoke, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 204, Brussels, Belgium|Forest Investigative Site 203, Jette, Belgium|Forest Investigative Site 155, Toronto, Ontario, Canada|Forest Investigative Site 228, Antioquia, Bello, Colombia|Forest Investigative Site 227, Barranquilla, Colombia|Forest Investigative Site 226, Bogota, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron Cedex, Rhone, France|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 382, Gyula, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 580, Kielce, Poland|Forest Investigative Site 576, Tyniec Maly, Poland|Forest Investigative Site 577, Warsaw, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 676, Bellville Cape Town, South Africa|Forest Investigative Site 729, Barcelona, Spain|Forest Investigative Site 728, Sabadell, Spain|Forest Investigative Site 730, Torremolinos, Spain|Forest Investigative Site 803, Donetsk, Ukraine|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 802, Kherson, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine|Forest Investigative Site 801, Odessa, Ukraine		https://ClinicalTrials.gov/show/NCT01592773
107	NCT01592786	An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)		Completed	Has Results	Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Drug: Memantine Hydrochloride (HCl)	Number of Confirmed Social Responsiveness Scale (SRS) Responders	Forest Laboratories	All	6 Years to 12 Years   (Child)	Phase 2	906	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MEM-MD-91	June 2012	July 2013	August 2013	May 7, 2012	August 7, 2014	August 7, 2014	Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 066, Irvine, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 124, Orlando, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 114, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 123, Fort Wayne, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 084, Indianapolis, Indiana, United States|Forest Investigative Site 106, Wichita, Kansas, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 074, Owensboro, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 091, New Orleans, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 098, Bronx, New York, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 177, Camperdown, New South Wales, Australia|Forest Investigative Site 204, Brussel, Belgium|Forest Investigative Site 203, Bruxelles, Belgium|Forest Investigative Site 202, Hoboken, Belgium|Forest Investigative Site 201, Leuven, Belgium|Forest Investigative Site 155, Toronto, Ontario, Canada|Forest Investigative Site 227, Barranquilla, Colombia|Forest Investigative Site 228, Bello, Colombia|Forest Investigative Site 226, Bogota, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron, Rhone, France|Forest Investigative Site 326, Paris, France|Forest Investigative Site 379, Budapest, Hungary|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 382, Gyula, Hungary|Forest Investigative Site 380, Szeged, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 580, Kielce, Poland|Forest Investigative Site 576, Kobierzyce, Poland|Forest Investigative Site 577, Warszawa, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 651, Singapore, Singapore|Forest Investigative Site 676, Cape Town, Western Cape, South Africa|Forest Investigative Site 728, Sabadell, Barcelona, Spain|Forest Investigative Site 730, Torremolinos, Málaga, Spain|Forest Investigative Site 729, Barcelona, Spain|Forest Investigative Site 727, Madrid, Spain|Forest Investigative Site 802, Kherson, Vil. Stepanivka, Ukraine|Forest Investigative Site 803, Donetsk, Ukraine|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine|Forest Investigative Site 801, Odesa, Ukraine		https://ClinicalTrials.gov/show/NCT01592786
108	NCT03202303	Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)		Recruiting	No Results Available	Autism Spectrum Disorder	Drug: Cannabidivarin|Drug: Matched Placebo	Aberrant Behavior Checklist-Irritability Subscale (ABC-I)|Repetitive Behavior Scale-Revised (RBS-R)|Aberrant Behavior Checklist-Social Withdrawal Subscale (ABC-SW)|Pediatric Quality of Life Inventory (PedsQL) Family Impact Module|Vineland Adaptive Behavior Scale-3 (Vineland 3)|Clinical Global Impressions-Improvement (CGI-I)|Montefiore Einstein Rigidity Scale-Revised (MERS-R)	Montefiore Medical Center|United States Department of Defense|Jazz Pharmaceuticals	All	5 Years to 18 Years   (Child, Adult)	Phase 2	100	Other|U.S. Fed|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2017-8538|AR160104|G32379	April 12, 2019	July 31, 2023	July 31, 2023	June 28, 2017		September 22, 2022	Montefiore Medical Center, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT03202303
109	NCT01592747	Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine		Completed	Has Results	Autistic Disorder|Autism|Asperger's Disorder|Asperger Syndrome|Autism Spectrum Disorders|Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)	Drug: Memantine Hydrochloride (HCl)|Drug: Placebo capsules	Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)|Time to First Loss of Therapeutic (LTR) Response|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12	Forest Laboratories	All	6 Years to 12 Years   (Child)	Phase 2	479	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MEM-MD-68	September 2012	September 2013	October 2013	May 7, 2012	April 24, 2019	April 24, 2019	Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 106, Wichita, Kansas, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 204, Brussel, Belgium|Forest Investigative Site 203, Bruxelles, Belgium|Forest Investigative Site 228, Bello, Colombia|Forest Investigative Site 226, Bogotá, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron Cedex, France|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 576, Kobierzyce, Poland|Forest Investigative Site 577, Warszawa, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 676, Cape Town, Western Cape, South Africa|Forest Investigative Site 728, Sabadell, Barcelona, Spain|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 802, Kherson,Vil. Stepanivka, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine		https://ClinicalTrials.gov/show/NCT01592747
110	NCT02611921	Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder		Completed	No Results Available	Autism Spectrum Disorder	Drug: Ketamine|Drug: Placebo	Change in Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)|Change in the Clinician-rated CGI Improvement scale (CGI-I)	Children's Hospital Medical Center, Cincinnati|Roivant Sciences, Inc.|Cures Within Reach	All	12 Years to 30 Years   (Child, Adult)	Phase 1	21	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2015-2494	December 22, 2015	May 7, 2018	May 7, 2018	November 23, 2015		October 12, 2018	Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT02611921
111	NCT03919721	Field Test of Motivity.Net Software for Data Collection During Behavioral Interventions		Unknown status	No Results Available	Autistic Disorder	Behavioral: Applied Behavioral Analysis	Impact of software on number of updates to programs made by behavior analysts (intervention agility)|Event tracking usability assessed by user ratings|Program editing efficiency as assessed by usage analysis|Impact of software on trial success rate|Impact of software on trials to criterion (number of trials needed to achieve mastery)|Impact of software on total number of targets mastered	Experiad LLC|National Institute of Mental Health (NIMH)|University of Washington|northwest behavioral associates	All	2 Years to 21 Years   (Child, Adult)	Not Applicable	12	Industry|NIH|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	Motivity-II|R44MH098476	November 1, 2019	March 31, 2020	March 31, 2020	April 18, 2019		April 18, 2019	Northwest Behavioral Associates, Bellevue, Washington, United States		https://ClinicalTrials.gov/show/NCT03919721
112	NCT02202421	T-ABA Group Based Early Intervention For Parents of Children With ASD	T-ABA	Terminated	No Results Available	Autism	Behavioral: Targeted Applied Behavior Analysis (T-ABA)	Increase in child utterances|Child communication|Autism and other behavioral symptoms|Language Scores|Adaptive Behavior|Eye Tracking|Global Functioning|Quality of Life	The Cleveland Clinic|O'Neill Foundation|CVS Caremark	All	24 Months to 71 Months   (Child)	Not Applicable	21	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCF IRB 14-429	January 2015	April 2017	April 2017	July 29, 2014		October 24, 2017	Cleveland Clinic Center for Autism, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT02202421
113	NCT02176317	Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)		Completed	No Results Available	Autism Spectrum Disorder	Biological: Autologous Umbilical Cord Blood	Number of participants with non-serious and serious adverse events.|The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II	Duke University|The Marcus Foundation|PerkinElmer, Inc.	All	24 Months to 72 Months   (Child)	Phase 1	25	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00052449	June 2014	December 2015	December 2015	June 27, 2014		December 3, 2019	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02176317
114	NCT00889538	Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems		Completed	No Results Available	Autism|Severe Behavior Disorder	Drug: placebo|Drug: glutathione|Drug: glutathione, vit C and NAC	Improvement in both developmental skills and behavior with either glutathione or glutathione, Vitamin C and N-acetylcysteine therapy as compared to placebo therapy. Subjects will also be monitored using clinical and laboratory safety parameters.|Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio	University of Louisville|Cumberland Pharmaceuticals|Norton Healthcare	All	5 Years to 16 Years   (Child)	Not Applicable	24	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Glutathione-KCPCRU-01	April 2009	September 2012	September 2012	April 29, 2009		December 7, 2016	KCPCRU, Louisville, Kentucky, United States		https://ClinicalTrials.gov/show/NCT00889538
115	NCT01620060	Lurasidone Pediatric Pharmacokinetics Study		Completed	Has Results	Schizophrenia|Autism	Drug: Lurasidone	Lurasidone Primary Pharmacokinetic Parameters|Lurasidone Peak Serum Concentration (Cmax)|Number of Participants With Serious Adverse Events and Non-serious Adverse Events	Sunovion	All	6 Years to 17 Years   (Child)	Phase 1	105	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D1050300	June 2012	May 2013	May 2013	June 15, 2012	July 31, 2014	April 8, 2016	Woodland International Research Group, Inc., Little Rock, Arkansas, United States|Woodland Northwest Research, LLC, Springdale, Arkansas, United States|World Wide Research Centers Inc., Murrietta, California, United States|Segal Institute for Clinical Research, Ft. Lauderdale, Florida, United States|Miami Children's Hospital, South Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|University of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Aspen Clinical Research, Orem, Utah, United States		https://ClinicalTrials.gov/show/NCT01620060
116	NCT01141595	Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders		Completed	Has Results	Autism Spectrum Disorder	Drug: sapropterin dihydrochloride	Preschool Language Scales	The University of Texas Health Science Center, Houston|BioMarin Pharmaceutical	All	2 Years to 6 Years   (Child)	Not Applicable	10	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HSC-MS-09-0578	July 2010	September 2011	September 2011	June 10, 2010	February 24, 2014	April 1, 2014	Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States		https://ClinicalTrials.gov/show/NCT01141595
117	NCT04518358	Expert Guiding Technology to Help Individuals With Developmental Challenges Build Life and Vocational Skills		Unknown status	No Results Available	Autism Spectrum Disorder|Intellectual Disability	Behavioral: Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges	Fidelity of Treatment Implementation|Independent Completion of Steps|Number of Sessions to Skill Acquisition	John T. Nosek|Guiding Technologies Corporation	All	Child, Adult, Older Adult	Not Applicable	8	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1R43MH121230-01	September 1, 2019	August 31, 2021	August 31, 2021	August 19, 2020		August 19, 2020	Chimes Delaware, Newark, Delaware, United States		https://ClinicalTrials.gov/show/NCT04518358
118	NCT00848874	Portable Visual Guidance System Phase II	PVGS-II	Completed	No Results Available	Asperger Syndrome|High Functioning Autism	Behavioral: PVGS	Students who use the PVGS will demonstrate improved classroom social pragmatics and executive functioning.	Minna Levine, PhD|SymTrend Inc.|University of North Carolina, Chapel Hill	All	11 Years to 21 Years   (Child, Adult)	Not Applicable	47	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2R41MH075162|NIHM_2R41MH75162--02A1	September 2008	March 2010	March 2010	February 20, 2009		October 9, 2018	SymTrend, Inc., Belmont, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00848874
119	NCT02911194	a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)	A2MT	Completed	No Results Available	Autism|Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder	Dietary Supplement: a2 milk|Dietary Supplement: a1 containing milk	Change in Childhood Autism Rating Scale (CARS2-HF) Value during intervention|Change in Conners' Rating Scale - Revised (L) value during intervention.|Amino acid analysis of urine samples by mass spectroscopy.|Metabolomic analysis of blood spot samples by mass spectroscopy.|Changes to the gut microbiome profile.|Changes to stool appearance measured using the Bristol Stool Chart.	Northumbria University|ESPA Research|a2 Milk Company Ltd.	Male	5 Years to 10 Years   (Child)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	SUB017_Lodge_031115	September 2016	September 2018	September 2018	September 22, 2016		September 5, 2018	ESPA Research, Sunderland, Tyne And Wear, United Kingdom		https://ClinicalTrials.gov/show/NCT02911194
120	NCT04535817	Xolair Interventional Study in ASD Patients With Comorbid Atopy		Withdrawn	No Results Available	Autism Spectrum Disorder|Atopy	Drug: Omalizumab Injection [Xolair]	Change from Baseline to Week 12 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 24 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 48 in Social Responsiveness Scale (SRS) Edition 2|Change from Week 24 to Week 48 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 12 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 24 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 48 in Aberrant Behavior Checklist (ABC)|Change from Week 24 to Week 48 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 1 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 4 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 8 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 12 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 16 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 20 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 24 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 48 in Autism Treatment Evaluation Checklist (ATEC)|Change from Week 24 to Week 48 in Autism Treatment Evaluation Checklist (ATEC)|Inflammatory Marker Levels|Structural MRI|Functional MRI (resting state)|Generalized Anxiety Disorder 7-item (GAD-7)|Epworth Sleepiness Scale (ESS)|Pittsburgh Sleep Quality Index (PSQI)|Asthma Control Test (ACT)|Rhinitis Control Assessment Test (RCAT)|Validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD)	Beth Israel Deaconess Medical Center|Novartis	All	18 Years to 30 Years   (Adult)	Phase 1	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020P000753	January 1, 2021	January 1, 2022	January 1, 2022	September 2, 2020		August 18, 2021	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04535817
121	NCT00261508	A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)		Completed	No Results Available	DCild Development Disorders, Pervasive|Autistic Disorder|Developmental Disabilities|Asperger Syndrome|Rett Syndrome	Drug: risperidone	Change in the Irritability Subscale of the Aberrant Behavior Checklist (ABC) and other ABC subscales at end of treatment compared with baseline|Change from baseline to end of treatment in Nisonger Child Behavior Rating Form (N-CBRF), Visual Analogue Scale (VAS), and Clinical Global Impression (CGI); incidence of adverse events throughout study.	Janssen-Ortho Inc., Canada	All	5 Years to 12 Years   (Child)	Phase 3	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	CR006106	August 1999		December 2001	December 5, 2005		January 24, 2011			https://ClinicalTrials.gov/show/NCT00261508
122	NCT03605368	VR Intervention to Improve Police Safety		Recruiting	No Results Available	Autism Spectrum Disorder|Autism	Behavioral: Virtual Reality Intervention|Behavioral: Video Modeling Intervention	Change in Live Police Interaction Assessment Scores from Pre-to-Post treatment|Change in Police Interaction Knowledge|Learned skill improvements - Phase IIb only	Children's Hospital of Philadelphia|Floreo, Inc.|National Institute of Mental Health (NIMH)	All	12 Years to 60 Years   (Child, Adult)	Not Applicable	96	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	17-014387|1R42MH115539-01	November 28, 2017	August 2022	August 2022	July 30, 2018		November 26, 2021	Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03605368
123	NCT03514134	Modifying (Phase I) and Evaluating (Phase II) Virtual Reality Job Interview Training for Youth in Transition		Active, not recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Virtual Reality Job Interview Training|Behavioral: Services as Usual	Change in Job Interview Skills|Change in Job Interview Self-Efficacy|Change in Job Interview Motivation|Change in Job Interview Anxiety|Change in Employment Outcomes	University of Michigan|University of Wisconsin, Madison|SIMmersion, LLC	All	16 Years to 21 Years   (Child, Adult)	Not Applicable	71	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	HUM00129575	October 1, 2018	May 20, 2021	July 1, 2022	May 2, 2018		January 6, 2022	University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT03514134
124	NCT01172509	TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers		Terminated	No Results Available	Autism	Drug: R-baclofen	percent of baseline TMS-induced measures of (1) human synaptic plasticity (LTD)	Gonzalez-Heydrich, Joseph, M.D.|Boston Children's Hospital|Seaside Therapeutics, Inc.	All	18 Years to 30 Years   (Adult)	Phase 1	6	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	TMS_biomarker_Rbac_normals1	October 2010	July 2012	July 2012	July 29, 2010		August 21, 2015	Berenson-Allen Center for Noninvansive Brain Stimulation Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01172509
125	NCT04475848	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants		Completed	No Results Available	Autistic Disorder|Autism Spectrum Disorder|Child Development Disorders, Pervasive|Mental Disorders|Neurodevelopmental Disorders	Drug: RO6953958|Drug: Placebo|Drug: Midazolam	Parts 1, 2 and 3: Percentage of Participants with Adverse Events|Part 2: Change in suicide risk assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)|Parts 1, 2 and 3: Maximum Observed Plasma Concentration (Cmax) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2 and 3: Average Plasma Concentration (Cavg) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 1, 2 and 3: Time to Reach Maximum Observed Plasma Concentration (Tmax) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 1: Last Quantifiable Concentration (Clast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Time To the Last Quantifiable Concentration (Tlast) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 1, 2 and 3: Terminal Elimination Phase Half-Life (t1/2) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2 and 3: Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 1: Area Under the Plasma Concentration Versus Time Curve From Zero to 12h Postdose (AUC(0-12h)) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 1: Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 1: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 1, 2 and 3: Apparent Clearance (CL/F) of RO6953958|Parts 1, 2 and 3: Apparent Volume of Distribution (V/F) of RO6953958|Parts 1 and 2: Cumulative Amount of Unchanged Drug Excreted into the Urine (Ae) of RO6953958|Parts 1 and 2: Fraction of the Administered Drug Excreted into the Urine (Fe) of RO6953958|Parts 1 and 2: Renal Clearance of the Drug from Urine (CLR) of RO6953958|Parts 1, 2 and 3: Trough Plasma Concentration (Ctrough) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2 and 3: Accumulation Ratio based on AUC (RAUC) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2 and 3: Accumulation Ratio Based on Cmax (RCmax) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 1, 2 and 3: Accumulation Ratio based on Ctrough (RCtrough) of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 1, 2 and 3: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 1, 2 and 3: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 3: Tmax of Midazolam|Part 3: Cmax of Midazolam|Part 3: T1/2 of Midazolam|Part 3: AUClast of Midazolam|Part 3: AUCinf of Midazolam|Part 3: VF of oral Midazolam|Part 3: RAUC of Midazolam|Part 3: RCmax of Midazolam|Part 3: CL: Total Plasma Clearance of IV Midazolam|Part 3: Fraction Absorbed (F) of Midazolam|Part 3: Volume of Distribution under Steady-state Conditions (Vss) of Midazolam	Hoffmann-La Roche	Male	18 Years to 55 Years   (Adult)	Phase 1	88	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BP41695|2019-004486-41	July 15, 2020	February 6, 2022	February 6, 2022	July 17, 2020		February 16, 2022	Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04475848
126	NCT01914393	Pediatric Open-Label Extension Study		Completed	Has Results	Schizophrenia|Autism|Bipolar Depression	Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed	Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)|Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score|Change From Baseline in PANSS Positive Subscale Score|Change From Baseline in PANSS Negative Subscale Score|Change From Baseline in PANSS General Psychopathology Subscale Score|Change From Baseline in PANSS Excitability Subscale Score|Change From Baseline in the Clinical Global Impression -Severity Score|Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score|Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score|Change From Baseline in Clinical Global Impression (CGI) - Severity Score|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)|Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score|Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score|Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score|Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score|Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score|Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score	Sunovion	All	6 Years to 17 Years   (Child)	Phase 3	702	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D1050302|2013-001694-24	September 30, 2013	October 17, 2018	October 17, 2018	August 2, 2013	December 19, 2019	December 19, 2019	Harmonex Neuroscience Research, Dothan, Alabama, United States|Diligent Clinical Trials, Inc, Downey, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Sarkis Clinical Trials - Parent, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|APG Research, LLC, Orlando, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|Medical Research Group of Central Florida, Sanford, Florida, United States|University of South Florida Rothman Center of Neuropychiatry, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Attalla Consultants, LLC, Smyrna, Georgia, United States|Psychiatric Associates, Overland Park, Kansas, United States|University Of Kentucky, Lexington, Kentucky, United States|Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Neurobehavioral medicine Group, LLC, Bloomfield Hills, Michigan, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|North Shore/Long Island Jewish PRIME, Glen Oaks, New York, United States|Dr. Jeanette Cueva, Mount Kisco, New York, United States|Montefiore Medical Center PRIME, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|Family Psychiatry of The Woodlands, P.A., The Woodlands, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Clinical Research Partners, LLC, Petersburg, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|MHC - Ruse, EOOD, Ruse, Bulgaria|UMHAT "Alexandrovska" EAD, Sofia, Bulgaria|MHAT-Targovishte, AD, Targovishte, Bulgaria|DCC "Mladost M" - Varna, OOD, Varna, Bulgaria|Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia|E.S.E. Hospital Mental de Antioquia, Bello, Colombia|Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda, Bogota, Colombia|CHU Nantes - Hôpital Mère-Enfant, Nantes Cedex 1, France|Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert, Budapest, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Seoul National University Hospital, Seoul, Gyeonggi-do, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C., Culiacan, Sinaloa, Mexico|Dr. Jessica Rosas Escobar, Durango, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Mexico|Instituto de Informacion de Investigacion en Salud Mental, Monterrey, Mexico|Av Modesto Arreola #917 Ote. Col Centro, Nuevo León, Mexico|Alexian Brothers Health and Wellness Center, Davao City, Philippines|West Visayas State University Medical Center, Iloilo, Philippines|National Center for Mental Health, Mandaluyong City, Philippines|Veterans Memorial Medical Center, Quezon City, Philippines|NZOZ Poradnia Zdrowia Psychicznego, Kobierzyce, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy, Toruń, Poland|Centro de Investigacion Clinica Psiquiatrica, Caguas, Puerto Rico|Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia, Bucuresti, Romania|Spitalul Clinic de Psihiatrie Socola, Iasi, Romania|Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara, Timisoara, Romania|Sverdiovsk Regional Clinical Psychiatric Hospital, Ekaterinburg, Russian Federation|GUZ Lipetsk Regional psychoneurological Hospital #1, Lipetsk, Russian Federation|Closed corporation "Scientific Center of Personalized Psychiatry", Moscow, Russian Federation|Scientific Center of Personalized Psychiatry, Moscow, Russian Federation|State Healthcare Institution of Nizhniy Novgordo region "Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod", Nizhny Novgorod, Russian Federation|SHI "City Psychoneurological dispensary #7 (with Hospital)", Saint Petersburg, Russian Federation|Center of Recovery Treatment "Pediatric Psychiatry" named after S.S. Mnukhin, Saint Petersburg, Russian Federation|Bekhterev Institute, Saint Petersburg, Russian Federation|Regional Clinical Mental Hospital of Saint Sofiya, Saratow, Russian Federation|FSBSI "Scientific Research Institute of Mental Health", Tomsk, Russian Federation|State Healthcare Institution of Yaroslavl Rgion "Yaroslavl Regional clinical Mental Hospital", Yaroslavl, Russian Federation|Hospital Marítimo de Torremolinos, Torremolinos, Málaga, Spain|RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU, Ivano Frankivsk, Ukraine|SI Institute of Neurology, Psychiatry and Narcology of NAMSU, Kharkiv, Ukraine|SI Institute of Children and Adolescents Healthcare of NAMSU, Kharkiv, Ukraine|TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions, Kyiv, Ukraine|CI Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine|Odesa Regional Psychoneurological Dispensary, Outpatient Dept., Odesa, Ukraine|O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy, Poltava, Ukraine|CI Kherson Regional Psychiatric Hospital of Kherson RC, Stepanivka, Ukraine|Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU, Ternopil, Ukraine|Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI, Vinnitsia, Ukraine	"Study Protocol: Final Protocol", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01914393/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01914393/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT01914393
127	NCT05163717	INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD	CALM 201	Recruiting	No Results Available	Agitation in Adolescents and Young Adults With ASD	Combination Product: INP105|Combination Product: Placebo	Incidence of adverse events and serious adverse events in the INP105 and placebo groups up to 48 hours post-dose|Overall incidence of adverse events and serious adverse events in the INP105 and placebo groups|Change in Agitation-Calmness Evaluation Scale (ACES) score at 30 minutes post-dose|Change in Behavioral Activity Rating Scale (BARS) score at 30 minutes post-dose|Change in Overt Aggression Scale (OAS) score at 30 minutes post-dose|Change in Positive and Negative Syndrome Scale - Excited Component (PEC) score at 30 minutes post-dose|Change in irritability behavior frequency counts at 30 minutes post-dose|Clinical Global Impressions - Improvement (CGI-I) score at 30 minutes post-dose|Clinical Global Impressions - Efficacy (CGI-E) score at 30 minutes post-dose|Change in modified Aberrant Behavior Checklist - Irritability Subscale (ABC-I) score at 60 minutes post-dose|Time to reach an ACES score of 4 (normal) post-dosing|Frequency of administering pharmaceutical rescue intervention within 120 minutes after dosing	Impel Pharmaceuticals	All	12 Years to 21 Years   (Child, Adult)	Phase 2	32	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	INP105-201	June 23, 2022	January 2023	July 2023	December 20, 2021		October 25, 2022	Maine Behavioral Healthcare, Portland, Maine, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT05163717
128	NCT01745497	Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder		Completed	No Results Available	Autism Spectrum Disorder|Insomnia	Drug: Ferrous sulfate|Drug: Placebo	Improvement in sleep onset|Changes inDay time behavior|Improvements in sleep maintenance insomnia	University of Colorado, Denver|Autism Treatment Network|Massachusetts General Hospital|The Emmes Company, LLC|Health Resources and Services Administration (HRSA)	All	2 Years to 10 Years   (Child)	Phase 2	24	Other|Industry|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	12-0466	December 2012	August 2015	August 2015	December 10, 2012		August 3, 2020	Childrens Hospital Colorado, Aurora, Colorado, United States|University of Rochester, Rochester, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Hospital for Sick Children, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01745497
129	NCT01808066	GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs		Completed	Has Results	Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder|Pervasive Developmental Disorder|Asperger's Disorder	Device: Groundskeeper	Number of Participants With an Increase/Improvement in Focusing|Number of Participants Identified as Attentive, Interested and Motivated Via Pre Interview	CogCubed, Corp|Ohio University	All	5 Years to 12 Years   (Child)	Not Applicable	21	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12X226	January 2013	May 2013	May 2013	March 11, 2013	September 9, 2014	October 16, 2019	Ohio University, Athens, Ohio, United States		https://ClinicalTrials.gov/show/NCT01808066
130	NCT02776215	Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents		Unknown status	No Results Available	Circadian Rhythm Sleep Disorders|Non-24 Hour Sleep-Wake Disorder|Autism Spectrum Disorder|Smith-Magenis Syndrome	Drug: tasimelteon	Area under the curver (AUC) of tasimelteon and its metabolites|Maximum concetration (Cmax) of tasimelteon and its metabolites|Steady-state concentration (Css) of tasimelteon and its metabolites|Half-life of tasimelteon and its metabolites|Trough concentration (Ctrough) of tasimelteon and its metabolites|Safety and tolerability of tasimelteon as measured by spontaneous reporting of adverse events (AEs)|Safety and tolerability of tasimelteon as measured by Pediatric Adverse Event Reporting System (PAERS)	Vanda Pharmaceuticals	All	3 Years to 17 Years   (Child)	Phase 1	24	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VP-VEC-162-4201	September 2016	December 2018		May 18, 2016		March 1, 2017	Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02776215
131	NCT01050582	A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children		Completed	Has Results	Schizophrenia|Bipolar Disorder|Autistic Disorder|Conduct and Other Disruptive Behavior Disorders	Drug: Risperidone|Drug: Other atypical antipsychotic drugs	Height (cm) Z-score at Study Visit|Age (Years) at Current Tanner Stage|Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	8 Years to 16 Years   (Child)	Phase 4	244	Industry	Interventional	Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR016687|RISNAP4022	October 2009	July 2011	July 2011	January 15, 2010	November 27, 2012	November 27, 2012	San Francisco, California, United States|Aurora, Colorado, United States|Altamonte Springs, Florida, United States|Gainesville, Florida, United States|Smyrna, Georgia, United States|Naperville, Illinois, United States|Indianapolis, Indiana, United States|Valparaiso, Indiana, United States|Boston, Massachusetts, United States|Cambridge, Massachusetts, United States|Glen Oaks, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Antwerpen, Belgium|Freiburg, Germany|Jena, Germany|Mannheim, Germany|München, Germany|Tübingen, Germany|Ulm, Germany|Würzburg, Germany|Athens, Greece|Nijmegen, Netherlands|Gdansk, Poland|Kielce, Poland|Lódź, Poland|Sosnowiec, Poland|Warszawa N/A, Poland|Warszawa, Poland		https://ClinicalTrials.gov/show/NCT01050582
132	NCT00198055	A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.		Completed	No Results Available	Asperger's Disorder|Pervasive Developmental Disorder	Drug: aripiprazole	The Clinical Global Impression(CGI)Improvement Scale.|The Irritability subscale of the Aberrant Behavior Checklist (ABC)|The Clinical Global Impression Severity Scale.|The Compulsion subscale of the Children's Yale-Brown Obsessive-Compulsive(CY-BOCS).|The Vineland Maladaptive Behavior Subscale.	Indiana University School of Medicine|Bristol-Myers Squibb|Indiana University	All	4 Years to 17 Years   (Child)	Phase 2	25	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0302-24	January 2005	September 2007	September 2007	September 20, 2005		June 4, 2014	Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00198055
133	NCT03292848	Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders		Completed	No Results Available	ADHD|Autism|Bipolar I Disorder|Conduct Disorder|Oppositional Defiant Disorder	Drug: Brexpiprazole	Maximum Plasma Concentration (Cmax) [PK]|Area under concentration-time curve (AUC) calculated from time zero to time t (AUCt) [PK]|AUC from time zero to infinity [PK]|Time of maximum plasma concentration (tmax) [PK]|Terminal-phase elimination half-life (t½,z) [PK]|Apparent clearance of drug from plasma after extravascular administration (CL/F) [PK]|Treatment-Emergent Adverse Events (TEAES) [Safety]|Clinical laboratory tests [Safety]|Vital signs observed and change from baseline data (systolic and diastolic blood pressure) [Safety]|Vital signs observed and change from baseline data (heart rate) [Safety]|Vital signs observed and change from baseline data (respiratory rate) [Safety]|Vital signs observed and change from baseline data (body temperature) [Safety]|12-lead electrocardiogram (ECGs) [Safety]|Physical examinations (height) [Safety]|Physical examinations (weight) [Safety]|Physical examinations- Body Mass Index (BMI) [Safety]|Physical examinations- review of body systems [Safety]|Simpson-Angus Scale (SAS) rating scale [Safety]|Abnormal Involuntary Movement Scale (AIMS) [Safety]|Barnes Akathisia Rating Scale (BARS) [Safety]|Columbia-Suicide Severity Rating Scale (C-SSRS) [Safety]	Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S	All	6 Years to 12 Years   (Child)	Phase 1	24	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	331-201-00103	October 10, 2017	May 21, 2018	May 21, 2018	September 26, 2017		June 12, 2018	Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|Alliance for Wellness dba Alliance for Research, Long Beach, California, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Road Runner Research Ltd., San Antonio, Texas, United States|Aspen Clinical Research, Orem, Utah, United States		https://ClinicalTrials.gov/show/NCT03292848
134	NCT05565482	Work Chat: An Interactive Virtual Workday		Enrolling by invitation	No Results Available	Autism|Autism Spectrum Disorder	Behavioral: Work Chat: An Interactive Virtual Workday	Change in Social Cognition - Hinting Task|Change in Emotion Recognition Ability - MiniPONs|Change in Emotion Regulation - Emotion Dysregulation Inventory Short Form (Reactivity Index Short Form)|Greater Gains/Change in Workplace Functioning - Workplace Behavior Inventory (WBI)|Greater sustained employment by 9 Months|Change in Social Competence|Change in Perceived Social Self-Efficacy Scale (PSSE)|Change in Perceived Empathy Self-Efficacy Scale (PESE)|Change in Anxiety	University of Michigan|SIMmersion, LLC|Michigan Career and Technical Institute (MCTI)|National Institute of Mental Health (NIMH)|Michigan State University|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Not Applicable	725	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	HUM00216949|R44MH123359-01	October 13, 2022	October 10, 2024	January 10, 2025	October 4, 2022		November 3, 2022	Michigan Career and Technical Institute, Plainwell, Michigan, United States		https://ClinicalTrials.gov/show/NCT05565482
135	NCT00485849	A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD		Completed	No Results Available	Attention Deficit Hyperactivity Disorder	Drug: Atomoxetine Hydrochloride	Test whether atomoxetine is effective in reducing symptoms of inattention and overactivity/impulsivity as measured by the AHDHRS-IV-Parent:Inv scale in pediatric outpatients with ASD accompanied by ADHD behavior problems|To assess whether atomoxetine will be effective in reducing symptoms of inattention and overactivity/impulsivity|To assess whether atomoxetine will be effective for improving social functioning and personal sufficiency in children and adolescents with ASD+ADHD|To assess whether atomoxetine has a positive or negative effect on frequently associated symptoms as impulsive aggression, agitation, self-injurious behavior, troublesome repetitive behavior and poor motor coordination|To assess whether atomoxetine has a positive or negative effect on neuropsychological functioning|To assess the overall influence on functioning and burden on the family|To monitor clinical safety and side effects as assessed by adverse events elicited during open-ended questioning	Eli Lilly and Company	All	6 Years to 17 Years   (Child)	Phase 4	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6639|B4Z-UT-S003	February 2004		October 2004	June 13, 2007		June 13, 2007	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Groningen, Netherlands		https://ClinicalTrials.gov/show/NCT00485849
136	NCT01894958	A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome		Completed	No Results Available	Fragile X Syndrome	Drug: NNZ-2566|Drug: Placebo	Adverse events|Physiological changes|Behavior|Global and Functional outcome Measures	Neuren Pharmaceuticals Limited	Male	12 Years to 45 Years   (Child, Adult)	Phase 2	72	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Neu-2566-FXS-001	January 2014	September 2015	October 2015	July 10, 2013		February 5, 2018	UC Davis MIND Institute, Sacramento, California, United States|Children's Hospital Colorado, Denver, Colorado, United States|Children's National Hospital, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Nebraska, Omaha, Nebraska, United States|Mount Sinai School of Medicine, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Autism & Developmental Medicine Institute Geisinger Health System, Lewisburg, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01894958
137	NCT01854346	Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders	KONTAKT-RCT	Completed	No Results Available	Autism Spectrum Disorder (ASD)|Attention Deficit Hyperactivity Disorder (ADHD)|Anxiety|Depression	Behavioral: Social skills group training, KONTAKT	Social Responsiveness Scale (SRS)|Adaptive Behavior Assessment System II (ABAS II)|Developmental Disabilities Modification of the Children's Global Assessment Scale (DD-CGAS)|Clinical Global Impression-Improvement/Severity (CGI)|Samples With DNA	Karolinska Institutet|Child and Adolescent Psychiatry, Stockholm|Region Stockholm|Stiftelsen Sunnerdahls Handikappfond|The Swedish Research Council|The Pediatric Research Foundation at Astrid Lindgren Children's Hospital|Majblomman	All	8 Years to 17 Years   (Child)	Not Applicable	296	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	KONTAKT	August 2012	March 2016	March 2016	May 15, 2013		August 22, 2017	Child & Adolescent Psychiatry Research Center, KIND, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT01854346
138	NCT01282268	Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome	Harbor-A	Completed	No Results Available	Fragile X Syndrome	Drug: arbaclofen|Drug: placebo	Aberrant Behavior Checklist - FXS Social Avoidance Subscale	Seaside Therapeutics, Inc.	All	12 Years to 50 Years   (Child, Adult)	Phase 3	125	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	209FX301	May 2011	December 2012		January 24, 2011		July 31, 2013	Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Miller Children's Hospital Research Administration, Long Beach, California, United States|University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States|Psychiatric Centers at San Diego, San Diego, California, United States|University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States|University of Miami, Mailman Center for Child Development, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Emory University School of Medicine, Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelpmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States|Duke University Clinical Research Unit, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|University of Oklahoma, Physician's Child Study Center, Oklahoma City, Oklahoma, United States|Suburban Research Associates/Elwyn Genetics, Media, Pennsylvania, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01282268
139	NCT01903681	Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances		Completed	No Results Available	Sleep Problems	Drug: Circadin 2 mg|Drug: Circadin 10 mg	baseline profile of endogenous saliva melatonin concentrations and urine 6-SMT excretion|concentration-time profile of saliva melatonin concentrations and 24 hour 6-SMT urine excretion after 2 and 10 mg Circadin® mini-tablets single dose administration|adverse event profile after a single dose of 2 or 10 mg Circadin® mini-tablets	Neurim Pharmaceuticals Ltd.	All	2 Years to 17 Years   (Child)	Phase 1	16	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CHDR1219	March 2013	February 2014	April 2014	July 19, 2013		April 4, 2014	Centre for Human Drug Research, Leiden, Netherlands		https://ClinicalTrials.gov/show/NCT01903681
140	NCT00870727	Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders		Completed	Has Results	Pervasive Developmental Disorder	Drug: Aripiprazole oral product|Drug: Placebo oral capsule	Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)|Mean Post-baseline Aberrant Behavior Checklist Irritability Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Stereotypy Subscale Score, Parent Report, Double-blind Phase	Indiana University|National Institute of Mental Health (NIMH)|Bristol-Myers Squibb	All	5 Years to 17 Years   (Child)	Phase 3	33	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	0805-26|MH 082119	February 2009	March 2015	May 2015	March 27, 2009	November 28, 2018	January 2, 2019	Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00870727
141	NCT00352196	Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study		Completed	No Results Available	Asperger's Disorder	Drug: Risperidone|Other: Magnetic Resonance Spectroscopy	Chang in the Scale for the Assessment of Negative Symptoms (SANS)|Change in Positive and Negative Symptom Scale (PANNS)|Change in Brief Psychiatric Rating Scale (BPRS)|Change in Montgomery Asberg Rating Scale (MADRS)|Change in Global Assessment Scale (GAS)|Change in Abnormal Involuntary Movement Scale (AIMS)|Change in Neurocognitive test battery	Augusta University|Ortho-McNeil Janssen Scientific Affairs, LLC	All	6 Years and older   (Child, Adult, Older Adult)	Phase 4	23	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RIS-EMR-4026|MCG HAC File #01-09-063	November 2001	May 2007	May 2007	July 14, 2006		January 14, 2015	Medical College of Georgia, Dept. of Psychiatry, Augusta, Georgia, United States		https://ClinicalTrials.gov/show/NCT00352196
142	NCT02715115	A Safety Study of NNZ-2566 in Pediatric Rett Syndrome		Completed	No Results Available	Rett Syndrome	Drug: NNZ-2566|Drug: Placebo	Adverse events|Motor Behaviour Assessment Scale (MBA)|Clinical Global Impression of Improvement (CGI-I)|Caregiver Top 3 Concerns via a Visual Analogue Scale (VAS)	Neuren Pharmaceuticals Limited|rettsyndrome.org	Female	5 Years to 15 Years   (Child)	Phase 2	82	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Neu-2566-RETT-002	March 2016	January 5, 2017	January 5, 2017	March 22, 2016		August 14, 2020	University of Alabama, Birmingham, Alabama, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of California, San Diego, San Diego, California, United States|Children's Hosptial Colorado, Aurora, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02715115
143	NCT01703533	A Safety Study of NNZ-2566 in Patients With Rett Syndrome		Completed	No Results Available	Rett Syndrome	Drug: NNZ-2566|Drug: Placebo	Adverse events|Change in EEG activity|Behavior|Physiological changes|Global and Functional outcome Measures	Neuren Pharmaceuticals Limited|Baylor College of Medicine|International Rett Syndrome Foundation	Female	16 Years to 45 Years   (Child, Adult)	Phase 2	67	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Neu-2566-RETT-001	March 2013	September 2014	September 2014	October 10, 2012		February 5, 2018	University of Alabama, Birmingham, Alabama, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Baylor School of Medicine, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01703533
144	NCT00919906	My Scrivener® - Measuring Effectiveness and Dose Response in Children		Completed	No Results Available	Asperger's Syndrome|Dyslexia|Cerebral Palsy|Attention Deficit Disorder|ADHD|Traumatic Brain Injury|Stroke	Device: My Scrivener(R)	Beery Motor Coordination Subtest|Print Tool and Cursive Tool|Deviations from desired 3-D writing path|Brief Assessment of Fine Motor Skills	Obslap Research LLC	All	5 Years to 19 Years   (Child, Adult)	Phase 1|Phase 2	176	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	002|#H133S070082	April 2009	September 2010	September 2010	June 12, 2009		October 28, 2010	Susan Palsbo, Eugene, Oregon, United States		https://ClinicalTrials.gov/show/NCT00919906
145	NCT03569631	A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome		Completed	No Results Available	Fragile X Syndrome|FXS|Fra(X) Syndrome	Drug: BPN14770|Drug: Placebo	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Tetra Discovery Partners	Male	18 Years to 45 Years   (Adult)	Phase 2	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BPN14770-CNS-203	July 9, 2018	July 31, 2020	July 31, 2020	June 26, 2018		December 3, 2020	Rush University Medical Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03569631
146	NCT03694275	A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)		Completed	Has Results	15q Duplication Syndrome|CDKL5 Deficiency Disease	Drug: Soticlestat	Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Maintenance Period|Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Treatment Period|Percentage of Participants Considered as Treatment Responders During the Maintenance Period|Percent Change From Baseline in Frequency of Motor Seizures Longer Than 5 Minutes in Participants With CDD|Proportion of Motor Seizure-free Days in Participants During the Maintenance Period|Change From Baseline in Clinician's Global Impression of Severity (CGI-S) Responses of Investigator|Percentage of Participants With Clinical Global Impression of Change (CGI-C) Responses as Per the Investigator Reported Impression|Percentage of Participants With Care Clinical Global Impression of Change (CGI-C) Responses of Parent/Family|Change From Baseline of Plasma 24S-hydroxycholesterol (24HC) Levels|Change From Baseline in Seizure Frequency in Participants Treated With TAK-935 as an Adjunctive Therapy	Takeda|Ovid Therapeutics Inc.	All	2 Years to 55 Years   (Child, Adult)	Phase 2	20	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TAK-935-18-002 (OV935)|U1111-1219-5787|2022-001315-44	September 10, 2018	July 13, 2020	July 31, 2020	October 3, 2018	April 20, 2021	May 26, 2022	UCLA, Los Angeles, California, United States|Research Institute Children's Hospital Colorado, Aurora, Colorado, United States|Center for Rare Neurological Diseases, Norcross, Georgia, United States|Center for Rare Neurological Diseases (CRND)--Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital Translational Neuroscience Center, Boston, Massachusetts, United States|Minnesota Epilepsy Group, P.A., Saint Paul, Minnesota, United States|New York University (NYU), New York, New York, United States|Columbia University Medical Center, New York, New York, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03694275/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03694275/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03694275
147	NCT01906866	Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities		Completed	Has Results	Sleep Disorders	Drug: Circadin 2/5/10 mg|Drug: Placebo	The Total Sleep Time Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary Questionnaire After the 13 Week, Double-blind Treatment Period.|Sleep Latency Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Duration of Wake After Sleep Onset Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Number of Awakenings During the Night Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Duration of the Longest Sleep Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Children's Social Functioning at Home, in School, and Community Settings Will be Measured for the Circadin 2/5 mg and Placebo by the Children Global Assessment Scale (CGAS) Questionnaire After 13 Weeks of Double-blind Treatment.|The Children's Behavior at Home, in School, and Community Will be Measured for the Circadin 2/5 mg and Placebo by the Strength of Difficulties Questionnaire (SDQ) Questionnaire Filled Out by the Parents After 13 Weeks of Double-blind Treatment.|The Number of Dropouts Between Circadin 2/5 mg to That of Placebo Will be Compared During the 13 Weeks of Double-blind Treatment.|Sleep Parameters (Rest/Activity Cycles) Will be Measured for the Circadin 2/5 mg and Placebo as Measured by Actigraphy After 13 Weeks of Double-blind Treatment.|Safety and Tolerability Throughout the Study Will be Measured for the Circadin 2/5 mg and Placebo Throughout the Study Using AE Eliciting Method Treatment Emergent Signs and Symptoms (TESS)|The Following Vital Signs Will be Measured: Blood Pressure, Pulse, Breathing and Body Temperature. They Will be Compared Between the Circadin and Placebo Groups.	Neurim Pharmaceuticals Ltd.	All	2 Years to 17 Years   (Child)	Phase 3	125	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	NEU_CH_7911	October 2013	March 27, 2018	March 27, 2018	July 24, 2013	October 30, 2018	May 21, 2019	Southwest Autism Research and Resource Center (SARRC), Phoenix, Arizona, United States|Crystal BioMedical Research, LLC, Miami Lakes, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Mate Lazlo, West Palm Beach, Florida, United States|Attalla Consultants LLC, dba Institue for Behabiovral medicine, Smyrna, Georgia, United States|AMR Baber research INC, Naperville, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Child Neurology Specialists/ CRCN, Henderson, Nevada, United States|Clinical research center of New Jersey, LLC, Voorhees, New Jersey, United States|Geinsinger Clinic, Danville, Pennsylvania, United States|The children's hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|INSITE Clinical Research, DeSoto, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Sleep Therapy & Research Center, San Antonio, Texas, United States|Road Runner Research, Ltd, San Antonio, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|Pacific institute of medical science, Bothell, Washington, United States|Helsinki Sleep Clinic Vitalmed OY, Helsinki, Finland|Hospital Raymond Poincare, Garches, France|Strasbourg University Hospital Depatment of Child Psychiatry & Neurology, Strasbourg,, France|Yulius Mental Health Organization, Dordrecht, Netherlands|Hospital Gelderse Vallei, Ede, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Birmingham Childrens Hospital NHS FOUNDATION TRUST, Birmingham, United Kingdom|Blackpool Victoria Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Guy's & St. Thomas's NHS Foundation Trust of St Thomas's Hospital, London, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/Prot_002.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/SAP_003.pdf	https://ClinicalTrials.gov/show/NCT01906866
148	NCT01289912	Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)	TSC	Completed	Has Results	Tuberous Sclerosis Complex	Drug: RAD001|Drug: Placebo	Evaluation of the Safety of RAD001 on Neurocognition in Patients With TSC Compared With Placebo in Patients With TSC.|Evaluation of the Efficacy of RAD001 on Neurocognition in Patients With TSC Compared With Placebo.|Evaluation of the Efficacy of RAD001 on Neurocognition (Cambridge Neuropsychological Test Automated Battery) in Patients With TSC Compared With Placebo.|Comparison of Absolute Change From Baseline in Frequency of Epileptiform Events Between Patients Taking RAD001 vs. Placebo|Comparison of Sleep Disturbances Between Patients Taking RAD001 vs. Placebo|Comparison of Autism Spectrum Disorders Features Between Patients Taking RAD001 vs. Placebo|Comparison of Academic Skills Between Patients Taking RAD001 vs. Placebo|Comparison of Behavioral Problems Between Patients Taking RAD001 vs Placebo	Mustafa Sahin|Tuberous Sclerosis Alliance|Autism Speaks|Novartis Pharmaceuticals|Seizure Tracker LLC|Boston Children's Hospital	All	6 Years to 21 Years   (Child, Adult)	Phase 2	52	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	10-06-0247	January 2011	December 2014	December 2014	February 4, 2011	January 25, 2018	January 25, 2018	Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT01289912
149	NCT02991807	RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome		Completed	No Results Available	PTEN Gene Mutation|PTEN Hamartoma Tumor Syndrome	Drug: RAD001|Drug: Placebo	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Change in Working Memory at 6 Months|Change in Processing Speed at 6 Months|Change in Fine Motor Skills at 6 Months|Change in Attention at 6 Months|Change in Impulsivity at 6 Months|Change in Global Cognitive Ability at 6 Months|Change in Motor Functioning at 6 Months|Change in Communication Ability at 6 Months	Boston Children's Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Sciences (NCATS)|Novartis Pharmaceuticals|PTEN Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	5 Years to 45 Years   (Child, Adult)	Phase 1|Phase 2	46	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	IRB-P00020332|1U54NS092090	June 12, 2017	February 18, 2021	December 22, 2021	December 14, 2016		February 8, 2022	Stanford University, Palo Alto, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT02991807
